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 Lysophospholipid acyltransferases (LPATs) catalyze the addition of an acyl chain 
to a lysophospholipid to form a phospholipid, dramatically altering lipid structure and 
behavior.  These changes influence membrane curvature, the processes of vesicle and 
membrane tubule biogenesis, and the structure and trafficking dynamics of secretory 
organelles.  At the beginning of my studies, I investigated the synergistic and 
antagonistic relationships between the activities of LPATs and phospholipases in 
regulating membrane trafficking.  I went on to identify, by performing an overexpression 
screen, the human LPAT isoforms that are most important for regulating secretory 
membrane trafficking.  I chose one of these enzymes for further characterization, the 
human membrane bound O-acyltransferase (MBOAT) gene family member 
lysophosphatidylcholine acyltransferase 3 (LPCAT3).  Using selective membrane 
permeabilization immunostaining, I determined the topological orientation of LPCAT3’s 
11 transmembrane domains and luminal active site.  I also found that a C-terminal 
K(x)KXX motif was necessary for LPCAT3 localization to the endoplasmic reticulum 
(ER).  I observed the influence of LPCAT3 activity on the structure and dynamics of the 
early secretory system, through overexpression which reduced soluble protein secretion 
  
to 22% of control and caused relocalization of COPI and COPII vesicle markers.  
Additionally, LPCAT3 knockdown had profound effects on retrograde trafficking from the 
Golgi and ER-Golgi intermediate complex (ERGIC) to the ER.  Knockdown slowed 
trafficking of the p58 receptor (ERGIC-53) and Brefeldin A induced recycling of Golgi 
phosphoprotein of 130 kDa to the ER.  Slowed retrograde transport was accompanied 
by increased membrane tubulation.  These effects of knockdown were reflected in the 
localization of ERGIC-53 and markers of COPII and COPI vesicles, which were 
mislocalized in knockdown cells.  However, the alteration of LPCAT3 expression levels, 
through knockdown or overexpression, did not disrupt the morphology of the Golgi 
complex, trans-Golgi network (TGN), adaptor protein 1 (AP-1)/clathrin-coated vesicles, 
or endosomes.  These results suggest that LPCAT3 activity is important for efficient 
COPI vesiculation, the production of retrograde membrane tubules, and the fusion of 
retrograde membrane tubules with the ER.  These findings support a novel role for 
LPAT activity in the regulation of COPI function, membrane tubulation, and retrograde 
trafficking to the ER.
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CHAPTER ONE:  General introduction 
Overview of the endomembrane system 
 When students are first introduced to the internal components of the mammalian 
cell, organelles are often explained metaphorically.  Though the organelle names may 
be difficult to remember, even the most casual student instantly understands the 
function and importance of a cellular trash can (lysosome), power plant (mitochondria), 
factory (endoplasmic reticulum), or post office (trans-Golgi network).  Locomotives on a 
railroad are a common metaphor for the movement of actin and microtubule motors as 
they transport vesicles (railcars); membrane bound small GTPases are the postal codes 
and addresses to which vesicles are delivered. 
 While these concepts are facile and not grossly misleading, they fail to capture 
the tremendous complexity of the mammalian cell.  They do not speak of the density 
with which the cell is packed full of disparate molecules, to the fidelity and specificity of 
protein function, or to the importance of the membrane enclosed compartments that 
segregate intracellular space.  To make these concepts clear, it is first necessary to 
briefly introduce the concept of enzyme kinetics. 
 Leonor Michaelis and Maud Menten first described the mathematical principles of 
enzyme catalyzed reaction1.  They showed that reaction speed is proportional to the 
concentration of enzyme and substrate, so that the reaction accelerates in response to 
increases in either concentration.  This is a powerful relationship that forms the basis for 
the evolution of the eukaryotic endomembrane system.  Take for instance the lysosome, 
which has evolved to recycle damaged or unneeded macromolecules and to reduce 
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them into their basic components.  It is enriched with macromolecule degrading 
hydrolases by the cell’s targeted transport systems.  Macromolecules are likewise 
labeled for recycling, transported by cellular trafficking systems, and concentrated at 
lysosomes.  The high local concentration of hydrolytic enzymes and substrates to be 
hydrolyzed, allows remarkably efficient enzymatic reactions.  These efficiencies would 
not be possible without the specific transport, segregation, and concentration 
mechanisms of the eukaryotic cell’s extensive endomembrane system. 
 Given the efficiency of specialized organelles, one may ask why cellular 
compartments are not further specialized.  Why do lysosomes possess all classes of 
hydrolase instead of being specialized to breakdown a single type of macromolecule?  
Could not further efficiencies be found in a class of lysosome specialized to breakdown 
proteins, another for lipids, and a third for nucleic acids? 
 One reason we do not see greater specialization is that the maintenance of high 
enzyme and substrate concentrations places significant demands on intracellular 
trafficking systems.  Rapid transport mechanisms must continuously renew an 
organelle’s supply of enzymes and substrates while simultaneously removing enzyme 
products.  These demands are compounded by the need for trafficking machinery to 
differentiate between organelles to ensure the fidelity and specificity of transport 
mechanisms.  For instance, the delivery of lysosomal nucleic acid hydrolases to the 
nucleus would have disastrous consequences for genomic integrity. 
Ensuring the rapidity and specificity of membrane trafficking requires significant 
energy expenditure and machinery with incredible complexity.  The complexity of 
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eukaryotic endomembrane systems is substantial enough to involve as much as half of 
the genome in the direct and indirect processes of membrane upkeep and trafficking.2  
Eukaryotic membrane trafficking is, arguably, the most complex of biological systems.  
Increased compartmentalization and specialization of organelles would yield energy 
savings from increased enzymatic efficiency; however this gain must be balanced 
against the increased demand of a further elaborated membrane trafficking system. 
 The organelles of the endomembrane system are responsible for the synthesis of 
all transmembrane proteins, secreted proteins, glycosylated proteins and most cellular 
lipids.  They were first delineated by George Palade through groundbreaking electron 
microscopy and cell fractionation experiments.  Palade characterized their structure, 
function, localization, variety, and ubiquity in eukaryotic life3.  His discoveries formed the 
foundation of modern cell biology and his striking electron micrographs (Figure 1-1) still 
inspire students of cell biology. 
 A simplified model of the endomembrane system depicts a series of membrane 
bounded compartments through which secretory cargos are sequentially transported 
(Figure 1-2).  The rough endoplasmic reticulum (RER), by virtue of membrane bound 
ribosomes, is the site at which secretory cargo is synthesized.4,5  From the endoplasmic 
reticulum (ER), secretory cargo proceeds via coat protein complex II (COPII) coated 
vesicles to the ER-Golgi intermediate complex (ERGIC) and Golgi complex, where they 
fuse and release their cargo.6  The ERGIC is thought to serve as an intermediate
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Figure 1-1:  Electron micrograph from Palade depicting organelles of the 
endomembrane system 
Abbreviations: CV: condensing vacuoles; GC: Golgi cisternae; SV: small peripheral ER-
Golgi transport vesicles; TR: transitional elements; LY: lysosome.  Reproduced from 
Palade et al4. 
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trafficking and sorting station between the ER and Golgi complex.  The Golgi complex is 
composed of a set of flattened, stacked cisternae at which secretory proteins are post-
translationally modified (glycosylated, sulfated, etc.) and subsequently transported by 
vesicle and tubule carriers to a variety of endocytic compartments, the plasma 
membrane (PM), and the extracellular space.7,8  These processes are collectively called 
anterograde membrane trafficking or secretion. 
 Intermingling with and parallel to the secretion system, the retrograde membrane 
trafficking system, also called the endocytic system, operates to retrieve proteins from 
anterograde compartments.  The endocytic system is also responsible for internalizing 
extracellular materials to serve as nutrients, for membrane turnover, or receptor 
downregulation.  The secretory and endocytic systems are not separate, independent 
systems but instead are interconnected pathways by which a single endomembrane 
system achieves homeostasis. 
 Transport of secretory and endocytic cargo between organelles takes place 
through membrane enclosed vesicular and tubular intermediates.  Vesicles are, very 
generally speaking, spheres of 70-100 nm in diameter that form through a budding 
reaction catalyzed by organelle specific coat proteins9.  The major classes of coat 
proteins are the ER-derived COPII coated vesicle, the ERGIC- and Golgi-derived COPI 
coated vesicles and the AP/clathrin coated vesicles which originate from the trans-Golgi 
network (TGN), endosomes, and PM.  After shedding their coat proteins, vesicles are 
stable until triggered to fuse with a target membrane and can be stored or transported 
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Figure 1-2:  Simplified diagram of the mammalian endomembrane system 
Reproduced from Bonifacino and Lippincott-Schwartz10. 
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long distances.  Membrane tubules on the other hand are ephemeral cylindrical 
membrane projections of 60-80 nm in diameter and a highly variable length.10 
 Our understanding of the details of the eukaryotic secretory and endocytic 
systems has grown since the discoveries of Palade and his colleagues.  Tremendous 
progress has been made to elucidate many of the molecular mechanisms of membrane 
trafficking.  This has culminated in the 2013 Nobel Prize for Physiology or Medicine 
being awarded to James Rothman, Randy Schekman, and Thomas Südhof for “their 
discoveries of machinery regulating vesicle traffic”.  Though, as we continue to learn 
and refine our techniques, we uncover new mysteries that force us to conclude that our 
understanding is not yet complete. 
Organelles and trafficking mechanisms of the mammalian 
endomembrane system 
  The mammalian ER is a network of flattened membrane sheets, tubules, and 
budding vesicles that extend through the cytoplasm and are continuous with the nuclear 
envelope11.  The ER is the site at which all transmembrane and luminal proteins of the 
endomembrane system are synthesized and because of this is often thought of as the 
‘beginning’ of the secretory system.  To synthesize a transmembrane or luminal protein, 
the protein’s mRNA transcript is first partially translated in the cytoplasm.  If the mRNA 
encodes an N-terminal ER signal sequence or a stretch of hydrophobic residues that 
can form a transmembrane domain, after these motifs are translated, they will be 
recognized by signal recognition particle (SRP) and further translation is halted.  SRP 
then binds to the rough ER through interaction with the SRP receptor and begins the 
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translocation of the nascent protein across the translocon (Sec61 complex)12.  Tightly 
associated with the ER, the complex of ribosome, mRNA, nascent protein, and 
translocon cotranslationally translocates the protein across the ER membrane.  During 
translation and protein maturation, a signal peptidase removes the N-terminal signal 
sequence if present, oligosaccharyl transferase complexes glycosylate the protein, and 
luminal chaperones assist protein folding4.  Failure of the protein to reach a stably 
folded state stimulates the process of ER associated degradation (ERAD) by which the 
protein is translocated to the cytoplasm and targeted for destruction by protein 
hydrolases13. 
 The ER synthesizes the bulk of cellular lipids in a region called the smooth ER, 
so named because of the low density of attached ribosomes.  These lipids include 
sphingolipids, ceramide, triglycerides, cholesterol, and phospholipids.  Phospholipid 
synthesis begins by glycerol-3-phosphate acyltransferase (GPAT) mediated acylation of 
the sn-1 position of glycerol-3-phosphate followed by lysophospholipid acyltransferase 
(LPAT) mediated acylation of the sn-2 position to form phosphatidic acid (PA).  PA is 
generally short-lived in the ER as it is quickly dephosphorylated by the enzyme 
phosphatidic acid phosphatase to create diacylglycerol (DAG)14.  DAG is then 
remodeled through CDP:choline or CDP:ethanolamine phosphotransferase into 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE), respectively15.  
Phosphatidylserine (PS) is created through head-group exchange from PC and PE 
through the enzymes phosphatidylserine synthase 1 (PSS1) and PSS2, respectively16.  
Phosphatidylinositol (PI) is synthesized by phosphatidylinositol synthase from CDP-
diacylglycerol and myo-inositol17. 
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 Transport of proteins and lipids out of the ER is accomplished by COPII transport 
vesicles which form at specialized export areas of the ER known as ER exit sites 
(ERES)18.  COPII vesicles form when the Sec12 guanine nucleotide exchange factor 
(GEF) activates the small GTPase Sar1 on the ER membrane and recruits a 
Sec23/Sec24 dimer, which in turn recruits a Sec13/Sec31 dimer19.  These components 
assemble into an oligomeric lattice that coats the budding vesicle20.  The Sec12 
dependent activation of Sar1 is stimulated by Sar1 interaction with COPII cargo, leading 
to concentration of cargo in COPII vesicles21.  Sec23 is a Sar1 GTPase-activating 
protein (GAP) and, in conjunction with Sec12, facilitates cargo recruitment by cycling 
Sar1 GTP/GDP state22.  Sec24 possesses cargo binding sites and will retain COPII 
cargo irrespective of Sar1 GTP/GDP state23.  The recruitment of Sec13/31 leads to the 
formation of positive membrane curvature and the stimulation of Sec23 GAP activity24.  
Sec13/31 is the final COPII component and its assembly is then sufficient to conclude 
the vesiculation process, as has been demonstrated with liposomes and in vitro 
reconstituted ER membranes20. 
 Most secreted proteins undergo COPII mediated transport and thus COPII cargo 
is diverse in structure and composition.  This diversity necessitates the formation of 
COPII vesicles with heterogeneous size and shape.  Diameters of ~70 nm are most 
common but some mammalian cell types, such as cells from the intestinal epithelium, 
will regularly generate 400 nm coated vesicles, indicating a great deal of plasticity in 
COPII coat structure25,26.  The recruitment of specific cargo proteins into COPII vesicles 
is known to be mediated by many mechanisms.  Certain ‘privileged’ cargo molecules 
that cycle between the ER and Golgi complex, such as the SNARE protein Bet1p, 
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interact directly with Sar1 and Sec23/24 via a cytoplasmic domain27.  The well-studied 
viral glycoprotein VSV-G is efficiently sorted into COPII vesicles by an EXD signal in its 
cytosolic carboxyl-terminus, that also interacts with Sar1 and Sec23/2428.  Specific 
sorting of soluble cargo is thought to occur, at least in part, through binding of 
glycoproteins to the p58 receptor (ERGIC-53)29.  These and other mechanisms assist 
ER export of specific cargo proteins, but these mechanisms are not necessary for all ER 
export, as secretion is the default trafficking pathway for ER synthesized proteins.  Non-
specific ER export, has been called the ‘default’, ‘bulk flow’, or ‘constitutive’ secretory 
pathway30. 
 The capacity of the ER to produce proteins and lipids is controlled by an 
autoregulatory system called the ER stress response or unfolded protein response 
(UPR).  UPR is used to dramatic effect in the maturation of a quiescent B-cell to an 
actively secreting plasma cell, which is accompanied by a dramatic ER expansion 
(Figure 1-3)31.  The UPR system senses protein misfolding and lipid imbalance through 
ER localized sensor proteins PERK, ATF6, and IRE1.  PERK is often the first sensor 
activated due to its sensitivity, followed by ATF6, and finally IRE1 in response to long-
term or abundant unfolded proteins32–35.  A multitude of pathways are activated by each 
sensor.  Collectively, these include the transcriptional upregulation of protein folding 
chaperones, antioxidative enzymes, lipid metabolism enzymes, and the attenuation of 
translation through the phosphorylation of eukaryotic initiation factor of translation 
(eIF2α)36.  If none of these steps are successful in restoring ER homeostasis, 
apopotosis is triggered through the PERK-ATF4-CHOP pathway and/or the IRE1-
TRAF2-ASK1 pathway37. 
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Figure 1-3.  Electron micrograph depicting intracellular membrane remodeling 
Proliferation of the ER during the differentiation of CH12 cells (murine B-cell 
lymphoma) from A) a quiescent state to B) a stimulated plasma cell in response to 
incubation with lipopolysaccharide.  Differentiation is accompanied by a 12-fold 
increase in IgM secretion.  N, nucleus; M, mitochondrion; L, lysosome; G, Golgi 
complex; arrowhead, RER; thin arrows, type C retroviruses; broad arrows, transitional 
elements of the ER.  Reproduced from Wiest et al31.  
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 The ERGIC, once known as the vesicular tubular cluster, is a highly dynamic 
structure that is positioned between the ER and the cis-Golgi.  The morphology of the 
ERGIC varies greatly based on cell fixation method.  The classic tubulovesicular 
structure is observed in chemically fixed cells, while flash freezing reveals a highly 
budded pleiomorphic structure38.  It is most often a single interconnected mass but can 
also be found as a collection of independent juxtanuclear clusters that intermittently 
exchange vesicles and membrane tubules39.  The ERGIC receives COPII cargo from 
the ER and then sorts and repackages escaped ER proteins into COPI coated carriers 
for retrograde transport.  From the ERGIC, COPI coated vesicles travel, often assisted 
by microtubule motors, to either the cis-Golgi or the ER (discussed further below)40.   
 ERGIC-53 is a cis-Golgi, ERGIC, and ER resident transport protein that was 
experimentally important in helping to define the structure of the ERGIC.  It is a single 
pass transmembrane protein with a short cytoplasmic sequence and a large luminal 
domain that directs its binding to mannosyl containing proteoglycans to facilitate their 
anterograde transport41.  Its continuous cycling between compartments by COPII and 
COPI machinery requires the recognition of signals in its luminal, transmembrane, and 
cytosolic domains.  The cytosolic domain contains a terminal di-phenylalanine motif that 
interacts with COPII and is required for efficient ER export42.  The transmembrane and 
luminal domains are important for ER-ERGIC-Golgi cycling, though the underlying 
mechanism is not well understood43.  Retrieval of ERGIC-53 to the ER is accomplished 
through specific interaction between COPI machinery and ERGIC-53’s cytoplasmic C-
terminal K(x)KXX motif42,44. 
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 The COPI coated vesicle was the first non-clathrin-coated vesicle to be identified 
and was thought to mediate anterograde transport through the Golgi complex45.  It is 
now known that COPI coated vesicles primarily mediate retrograde trafficking between 
Golgi cisternae, from the Golgi to the ER, and from the ERGIC to the ER.  It has also 
been found that COPI mediates ERGIC to Golgi anterograde trafficking40.  The 
assembly of COPI coat proteins is initiated by small GTPases of the ADP-ribosylation 
factor (Arf) family.  There are six mammalian isoforms (Arf1-Arf6) of which Arf1 is the 
best studied.  When cytosolic Arf1 is activated by the GEF activity of a Sec7 family 
transmembrane protein such as GBF1 (Golgi Brefeldin A-resistance factor 1), it 
specifically associates with the Golgi and ERGIC46.  The specificity of Arf1 localization is 
mediated by interaction with localized membrane proteins (e.g. the p24 family tethering 
proteins)47.  Activated, membrane bound Arf1 promotes membrane curvature formation 
by intercalation of an amphipathic, myristoylated α-helix into the membrane bilayer.  
Subsequently, Arf1 recruits COPI coatomer subunits to the membrane48,49.  The 
coatomer is composed of seven subunits that are organized into a trimeric subcomplex 
of α-COP, β´-COP, and ε-COP, and a tetramer of β-COP, γ-COP, δ-COP, and ζ-COP50–
52.  The interactions of p24 family members and the KDEL receptor with COPI coatomer 
help to recruit coatomer and ensure strong membrane binding.  The p24 family of 
tethers interacts with the γ subunit of coatomer through a cytosolic di-phenylalanine di-
basic motif, FFXX(K/R)(K/R)51,53.  Similarly, the KDEL receptor has a dibasic motif, 
KKXSXXX, that binds coatomer when the serine residue is phosphorylated54.  The 
luminal domain of the KDEL receptor binds luminal proteins that possess a KDEL motif 
and transports these proteins during COPI retrograde trafficking to the ER55,56. 
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 Transmembrane proteins, other than p24 and KDEL receptor, can be recruited to 
COPI vesicles if they possess a dilysine motif, K(x)KXX, in their carboxyl terminus.  
These dilysine motifs differ from the dibasic motifs of p24 and the KDEL receptor; they 
are recognized by α-COP or β-COP57,58.  The recruitment of cargo proteins into COPI 
vesicles requires GTP hydrolysis.  The requirement of GTP hydrolysis was 
experimentally determined using the poorly hydrolyzable GTP analogue GTPγS and Arf 
mutants that are locked into a GTP loaded state.  Both of these conditions efficiently 
form COPI vesicles with normal concentrations of p24 and KDEL receptor, but are 
completely devoid of cargo proteins59–66. 
 The only components that are necessary for COPI scission in an in vitro system 
using synthetic liposomes are Arf1 and the COPI coat components67.  Scission occurs 
due to the confluence of Arf1-GTP’s intrinsic membrane deformation activity and the 
activity of COPI to form curved membrane coat structures68.  In the absence of 
coatomer, Arf1-GTP forms membrane tubule structures that never undergo scission69.  
Scission is regulated and made more efficient by accessory proteins, including p24, 
Brefeldin-A ADP ribosylated substrate (BARS), endophilin, Arf GTPase activating 
protein 1 (ArfGAP1), PLD2, and 1-acylglycerol-3-phosphate O-acyltransferase 3 
(AGPAT3)70–73.  
 The scission of COPI buds into vesicles is followed by an uncoating process in 
which coatomer proteins dissociate from the vesicle.  Uncoating is dependent on 
ArfGAP activated hydrolysis of Arf1-GTP.  ArfGAP is a stoichiometric component of the 
COPI coat that is regulated by membrane curvature and interacts directly with cargo 
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proteins70,74–76.  Uncoated vesicles are then transported to their destination in the ER, 
ERGIC, or Golgi by microtubule motors and fuse with the destination compartment.  
While the details of the bidirectionality of COPI transport are still unclear and 
controversial, the differentiation of anterograde from retrograde COPI vesicles is 
dependent on vesicle composition39.  Notable determinants are the cargo proteins and 
the isoforms of the p24 cargo receptors, Rabs, Arfs, tethering proteins and COPI 
coatomer subunits that make up the vesicle65,77–83. 
 The Golgi apparatus is the final site at which proteins are processed and sorted 
before being transported to their destination84.  Between cells, the number of cisternae 
and stacks (independent sets of cisternae) varies greatly, but cisternae are invariable 
described as cis, medial, and trans.  The trans-Golgi should not be confused with the 
similarly named trans-Golgi network (TGN).  The cis, medial, and trans-Golgi form a 
continuous interconnected network, while the TGN is adjacent to the trans-Golgi but is 
not continuous with it.  Despite these distinctions, the TGN is often thought of as the 
final compartment of the Golgi complex85. 
 The nomenclature that classifies the subcompartments of the Golgi complex 
underscores the sequential nature of cargo progression86.  The biological imperative for 
the sequential passage of secretory cargo through the Golgi is likely due to protein 
glycosylation.  Glycosylation sites on protein cargoes are modified by the ordered action 
of a series of glycosyltransferases with polarized localization across the cisternae87. 
 Analysis of the movement of secretory cargo through the Golgi cisternae has 
sparked a great deal of controversy and the proposal of a succession of mechanistic 
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models.  The first of these was the ‘stable compartment’ model, which was followed by 
the ‘cisternal maturation’ model, then the ‘rapid partition’ model, and most recently the 
‘rim progression’ model.  The stable compartment model posited that Golgi cisternae 
maintain a constant position while cargo proteins are transported by COPI vesicles 
between adjacent cisternae88.  ‘Cisternal maturation’ instead proposes that cisternae 
progress in a cis to trans manner through the Golgi stack, retaining their maturing cargo, 
and exchanging cisternae specific Golgi resident enzymes through COPI trafficking. 
 Some of the first evidence against the stable compartment model came from the 
characterization of the cargo proteins contained in COPI vesicles, which are primarily 
Golgi and ER resident proteins and not secretory cargo proteins89,90.  A second piece of 
evidence was found by studying large secretory proteins such as algae scales and 
procollagen aggregates, which due to their size could not possibly be transported by 
COPI vesicles and thus must move in concert with maturing cisternae91,92.  The live 
imaging of yeast Golgi cisternae exchanging, in sequence, fluorescently-labeled cis-, 
medial-, and trans-Golgi enzymes is perhaps the most satisfying testament to the 
cisternal maturation model93,94.   
 The ‘rapid partitioning’ model was a response to live cell fluorescent microscopy 
measurements of stochastic and exponential cargo export kinetics, which could not be 
explained by cisternal maturation.  It postulates that the Golgi is subdivided into ‘phases’ 
that segregate processing enzymes from export machinery.  Phase separation of the 
Golgi and the rapid partitioning of cargo proteins between phases would explain the 
kinetics of cargo secretion95. 
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 The most recently proposed model of Golgi structure-function, called ‘rim 
progression,’ was proposed by Rothman and colleagues96.  Their experimental system 
was based on a reversibly aggregating FKBP mutant fused to a transmembrane cargo 
protein, which they called membrane ‘staples’ due to their distinctive appearance by 
electron microscopy, and an analogous soluble cargo.  They found that aggregated 
membrane staples remained fixed within the center of immobile and non-maturing Golgi 
cisternae for at least 5-6 h (the longest observation period), during which time, 
anterograde trafficking of aggregated soluble cargo proceeded normally.  The term ‘rim 
progression’ was derived from the localization of aggregated soluble cargo to cisternal 
rims during trafficking. 
 In a separate report, Luini and colleagues used a very similar model system to 
defend cisternal maturation97.  They fused a transmembrane cis-Golgi resident protein 
with the FKBP mutant to form ‘MANI-FM’.  Disaggregated MANI-FM was retained in the 
cis-Golgi by COPI mediated retrograde trafficking.  Aggregated MANI-FM was 
prevented from entering vesicles or membrane tubules.  Over the course of 20 minutes, 
aggregated MANI-FM relocalized from the cis-Golgi to the trans-Golgi. 
 Luini’s defense of the cisternal maturation model can be reconciled with the rim 
progression model.  Rothman observed that large cargo molecules (soluble aggregates) 
traffic by the progression of cisternal rims.  Membrane staples did not participate in rim 
progression because they were strictly localized to the center of cisternae and 
effectively excluded from rim progression.  Luini’s aggregated MANI-FM was distributed 
throughout cisternae, allowing trafficking by ‘rim progression.’ 
18 
 
 The cisternae and stacks of cisternae of the mammalian Golgi are interconnected 
by membrane tubules98,99.  Membrane tubules between Golgi stacks maintain organelle 
integrity and prevent fragmentation into many separate “mini-stacks100.”  Membrane 
tubules between adjacent cisternae may be important for the accelerated maturation 
and secretion of some cargo proteins such as the non-glycosylated albumin and 
proinsulin proteins101. 
 Due to the ephemeral nature of membrane tubules, their physiological 
significance has been met with occasional skepticism.  There is agreement that certain 
organelles, particularly the ERGIC and TGN, exhibit significant tubulation activity under 
normal cellular conditions, which can be visualized with GFP-tagged membrane 
proteins in live cells102,103.  Perhaps the greatest source of controversy, and also one of 
the field’s most important experimental systems, is the massive tubulation of the 
ERGIC, Golgi, TGN, and endosomal compartments that can be stimulated by 
perturbation of Arf GTP cycling.  The most common method is by incubation with the 
fungal metabolite Brefeldin A (BFA), a specific inhibitor of Arf GEF, which prevents 
COPI and AP-1 coat proteins from binding104–106.  Specific siRNA knockdown of Arfs or 
their GEFs will also replicate most aspects of the BFA phenotype 78,107,108. 
 The transport of membrane tubules is often assisted by the activity of microtubule 
motors 108–112.  The relocalization of Golgi markers to the ER in response to BFA 
treatment is inhibited by simultaneous treatment with microtubule depolymerizing 
drugs113. 
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 The relationship between vesicles and tubules is currently unclear.  Studies of 
vesicle formation have shown that coat proteins are necessary in vivo and sufficient in 
vitro for vesicle formation114.  The role of coat proteins in membrane tubulation is more 
subtle.  Electron microscopy studies have shown that coat proteins decorate membrane 
tubules, where they induce the formation of bulges115–117.  One model proposes that 
membrane tubulation sites are initiated by coat protein binding and membrane 
deformation73.  However, this theory discounts the numerous observations of 
spontaneous membrane tubulation in in vitro systems that do not contain coat 
proteins118–120.  It also does not adequately explain why BFA treatment stimulates 
membrane tubulation (i.e. when coat proteins cannot bind).  Additionally, transport via 
membrane tubules of VSV-G from the TGN to the PM is not dependent on coat 
proteins121,122. 
 A competing model for the genesis of membrane tubules deemphasizes the role 
of coat proteins.  It theorizes that coat proteins are one of many mechanisms by which 
membrane curvature can be promoted and tubules can be formed.  Membrane 
curvature is regulated by a combination of several mechanisms. 
Membrane curvature 
 Membrane curvature can be induced by protein intercalation into the lipid bilayer 
which disrupts the packing of adjacent lipids, as in the case of Arf1.  Its short, 
hydrophobic α-helix, called an ArfGAP1 Lipid Packing Sensor (ALPS) motif, directly 
induces membrane curvature by intercalation into a membrane123. 
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 Similarly, proteins are able to bend membranes by penetrating a single layer of 
the membrane with an amphipathic domain.  The result is a small difference between 
the surface areas of each side of the membrane, an effect called bilayer-coupling124.  
Since the effect of changing the membrane surface area is proportional to the original 
surface area, small vesicles are most affected by bilayer coupling while large 
membranes are nearly unaffected125.   
 Another mechanism by which protein-membrane interactions can induce 
membrane curvature is through the formation of a curvature stabilizing protein scaffold.  
The BAR domain, an anti-parallel dimer of curved α-helices, is one example of 
membrane stabilizing protein scaffold.  Interactions of BAR domain containing proteins 
with the surface of the membrane stabilizes or promotes membrane bending to fit the 
BAR domain’s natural curvature 126.  Many BAR domain containing proteins, such as 
amphiphysin, endophilin, BRAP and nadrin have been shown to create membrane 
tubules in vitro126–129. 
 Lipids also affect the curvature of membranes.  Studies of artificial membrane 
systems make it clear that certain combinations of lipid species exhibit large 
spontaneous curvatures125.  Curvature is generated roughly in proportion to the ratio 
between the cross-sectional area of the hydrophilic head group and hydrophobic side 
chains.  For example, the PS head group is much larger than the head group of PA, and 
hence PS would favor positive membrane curvature and PA would not.  Similarly, 
phospholipids, having two acyl chains, contribute more negative curvature than 
lysophospholipids, which have a single acyl chain130–132. 
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 Lipids can also indirectly influence membrane curvature by recruiting lipid binding 
proteins to deform the membrane.  Epsin is an example of a membrane deforming 
protein that is recruited by the phospholipid phosphatidylinositol-4,5-bisphosphate 
(PIP2).  It deforms membranes by the insertion of an amphipathic helix region133,134.  
This and similar lipid specific protein recruitment events are an indispensable 
mechanism by which lipid remodeling can be linked to localized, transient changes in 
membrane curvature. 
 It is important to note that in live cells, membrane curvature is rarely affected by 
only one force in isolation.  It is sometimes the case that all of the above mechanisms 
are involved at a single tubulation or vesiculation site. 
Phospholipid remodeling 
 The enzyme classes that remodel phospholipid acyl chain composition are called 
phospholipase As (PLAs) and LPATs.  PLAs remove acyl chains through a hydrolysis 
reaction and LPATs re-esterify acyl chains.  The balance of activity between these two 
enzyme classes creates a dynamic and continuous process of acyl chain turnover 
called phospholipid remodeling. 
 The work of William Lands and colleagues in the 1960s first characterized 
phospholipid remodeling processes, and they are sometimes referred to as the “Lands 
cycle” in his honor.  This dissertation will focus on how the acyl chain composition of 
phospholipids and their remodeling influences intracellular membrane trafficking and the 
biogenesis of membrane vesicles and tubules.  However, phospholipid remodeling 
plays an important role in several other processes, whose discussion is beyond the 
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scope of this work.  They include the incorporation and release of arachidonic acid (AA) 
for the production of eicosanoids and prostaglandins135, production of platelet activating 
factor (PAF)136–138, the regulation of lipid droplet morphology139, triglyceride secretion 
via lipoprotein synthesis in the liver140, and the incorporation of host-derived fatty acids 
into membrane phospholipids in Giardia and other intracellular parasites141. 
Phospholipases 
 Phospholipases are a diverse class of soluble enzymes.  They are found in all life 
forms and cell types due to the essential utility of phospholipids in membranes.  
Phospholipases also have many specialized roles, such as in digestion, intracellular and 
extracellular signaling, as an active ingredient in many types of venom, and as an 
essential part of the defense and immune responses of plants and animals. 
 Phospholipases are differentiated into super families based on their preferred 
substrate and hydrolysis site.  These super families are phospholipase A1 (PLA1) and A2 
(PLA2), phospholipase B (PLB), phospholipase C (PLC), and phospholipase D (PLD) 
(Figure 1-4).  PLA1 and PLA2 produce lysophospholipids by hydrolyzing the sn-1 and 
sn-2 acyl chain of phospholipids, respectively.  Enzymes classified as PLB have PLA1 
and PLA2 activity and will hydrolyze both acyls chain of a phospholipid
142.  PLC 
produces DAG by hydrolyzing the phosphodiester linkage between glycerol and the 
head group.  PLD produces PA by hydrolyzing the bond between the head group and 
glycerophospholipid143–147.  A single super family is assigned to each phospholipase, 
however, many phospholipases have broad specificity that can overlap multiple super 
families or include non-phospholipid substrates148.  For example, pancreatic lipase   
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Figure 1-4.  Hydrolysis preference of phospholipase groups 
R represents acyl chains and X represents head groups (choline, ethanolamine, inositol, 
etc.)  Reproduced from Brown et al150.  
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related protein 2, a PLA2, hydrolyzes phospholipids, galactolipids, vitamin esters, and 
triglycerides149. 
 The PLA2 superfamily is divided into 15 groups but are more commonly 
referenced based on the classifications: secretory (sPLA2), cytosolic Ca
2+ dependent 
(cPLA2), cytosolic Ca
2+ independent (iPLA2), platelet-activating factor acetylhydrolases 
(PAFAH) and lysosomal150,151.  Of these, the classes cPLA2, iPLA2, and PAFAH are 
most relevant to intracellular membrane trafficking and together include four enzymes 
that are known to regulate membrane tubulation, cPLA2α, PAFAH Ib, iPLA2-β, and 
iPLA1γ. 
 The cPLA2 family, also known as Group IV, has six members, cPLA2 α, β, γ, δ, ε, 
and ζ.  These enzymes have a conserved active site dyad of serine and aspartic acid 
(S228/E529 in cPLA2α).  All but cPLA2γ contain an N-terminal α/β sandwich “C2 
domain” that binds Ca2+, regulates lipase activity, enables membrane translocation, and 
interfacial activation152.  Of the cPLA2 enzymes, cPLA2α is the most studied, due to its 
early discovery, ubiquitous expression, and importance in regulating eicosanoid 
signaling.  cPLA2α has a strong preference for sn-2 arachidonyl acyl chains, which are 
shunted into the production of the eicosanoids prostaglandins, thromboxanes, and 
leukotrienes.  Eicosanoids are local signaling molecules with many important roles, 
among them the regulation of the inflammatory response, immunity, and the nervous 
system153. 
 The role of cPLA2α in membrane trafficking was first suggested when increased 
cytoplasmic Ca2+ was shown to recruit cPLA2α to the Golgi complex
154.  It has also been 
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shown that cPLA2α is recruited to endothelial cells upon reaching confluence, where its 
activity is necessary for efficient transport of membrane proteins such as VE-cadherin, 
occluding, and claudin-5 to junction complexes155,156.  A bolus of secretory cargo has 
been shown to stimulate a transient increase in cytosolic Ca2+, translocation of cPLA2α 
to the Golgi complex, and cPLA2α mediated formation of intercisternal tubular 
connections to accelerate anterograde trafficking.  Conversely, blocking cPLA2α activity 
suppresses the formation of Golgi membrane tubules.  These effects are independent of 
changes in eicosanoid pathway throughput and are unaffected by arachidonic acid 
supplementation101. 
 The biological relevance of cPLA2α has yet to be convincingly established in a 
whole organism, as the growth and viability of the cPLA2α knockout mouse is 
phenotypically normal157.  However, there is one documented case of a human patient 
possessing two loss-of-function alleles for cPLA2α.  This patient exhibits decreased 
eicosanoid production, intestinal ulcers, and platelet dysfunction158,159.  While cPLA2α 
activity does not appear to be essential for efficient membrane trafficking, a siRNA 
screen of other PLA2s in a cPLA2α deficient cell line indicated that PAFAH Ib α1 may 
have a redundant role in supporting anterograde secretory transport101. 
 PAFAH Ib is an enzyme complex consisting of a dimer of two Ca2+-independent, 
Group VIII phospholipases of the PAFAH category and a dimer of Lis1 (gene name 
PAFAH Ib 1), a dynein regulator and a lissencephaly associated gene.  The catalytic 
complex can be either a homo- or hetero-dimer of PAFAH Ib α1 and α2 (gene names 
PAFAH Ib 2 and 3), paralogues with 63% amino acid identity, partially overlapping 
26 
 
substrate specificity, and slightly different expression pattern160–162.  The enzyme 
category, PAFAH, is derived from the ability of purified enzymes to hydrolyze the sn-2 
acetyl group from the extracellular lipid PAF163,164.  The physiological relevance of this 
activity for PAFAH Ib is dubious as it is a cytoplasmic enzyme complex.  Also, 
subsequent studies have shown that PAFAH Ib is not involved in organism-wide PAF 
signaling138. 
 The formation of membrane tubules and the maintenance of Golgi structure is 
influenced by PAFAH Ib activity, which was first shown using a chromatographically 
fractionated preparation of bovine brain cytosol.  The fraction containing PAFAH Ib was 
capable of stimulating Golgi membrane tubulation in an in vitro tubulation assay165.  
Later studies showed that tubulation activity is dependent on PAFAH Ib α1 and/or α2 
catalytic activity and that Lis1 is dispensable.  In cells however, α1, α2, and Lis1 are all 
important for regulating Golgi structure and function.  Knockdown of any of these 
enzymes causes the Golgi to fragment into mini-stacks110. 
 The iPLA2 enzyme family includes one member, iPLA2-β, a Group VI-2 PLA2, 
also known as PLA2G6 and PNPLA9, which has been shown to regulate ERGIC 
membrane trafficking135,166.  Double knockdown of Arf1 and Arf4 generates ERGIC 
membrane tubules and tubulation is dependent on iPLA2-β activity.  iPLA2-β-dependent 
tubulation is important for the transport of GFP-ERGIC-53 between ERGIC clusters.  
iPLA2-β also controls ERGIC tubulation and GFP-ERGIC-53 transport in wild-type cells 
without Arf knockdown.  Cells incubated at 16°C for 3 h accumulate GFP-ERGIC-53 in 
the ERGIC and can then be warmed to 37°C to stimulate tubulation.  Upon warming, 
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iPLA2-β translocated from the cytoplasm to GFP-ERGIC-53 labeled membrane tubules 
where its activity was necessary for tubulation166. 
 The final phospholipase that has been reported to be involved in membrane 
trafficking is iPLA1γ (gene name DDH2 or KIAA0725p), a Golgi and ERGIC localized 
protein.  Overexpression of iPLA1γ causes disorder of the Golgi and ERGIC as well as 
dispersion of Golgi associated tethering proteins167.  Two conflicting studies have been 
published, the first showing that iPLA1γ knockdown disrupts COPI- and Rab6-
independent Golgi-to-ER retrograde trafficking (such as BFA mediated Golgi recycling, 
but not COPI- and Rab6-dependent retrograde transport such as ERGIC-53 recycling).  
Also, knockdown did not affect VSV-ts045-GFP anterograde trafficking168.   The second 
study noted that the siRNA used in the first study had an unintended off-target effect 
that decreased Rab6 expression.  They went on to examine BFA induced retrograde 
trafficking with three other specific siRNAs and found no effects on retrograde 
trafficking, though VSV-ts045-GFP anterograde trafficking to the plasma membrane was 
slowed169. 
 Our understanding of phospholipases owes a great deal to the discovery and 
development of small molecule inhibitors170.  A pioneering study of small molecule PLA2 
inhibitors uncovered the PLA2 dependency of tubule-mediated retrograde trafficking and 
maintenance of the architecture of the Golgi complex171.  This study showed that 
treatment of mammalian cells with PLA2 inhibitors leads to fragmentation of the Golgi 
complex and suppresses BFA stimulated Golgi membrane tubulation.  Among the 
inhibitors tested was the irreversible membrane permeant small molecule bromoenol 
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lactone (BEL), which is a substrate analogue with 1000-fold selectivity to iPLA2s over 
cPLA2s.  BEL inhibits BFA mediated Golgi recycling with an IC50 of 4 μM and TGN 
tubulation at 20 μM.  It has become an indispensable reagent for testing phospholipase 
dependence in membrane trafficking studies.  Another important inhibitor is ONO-RS-
082 (ONO), which has reversible binding and an IC50 for BFA stimulated tubulation of 
the Golgi and TGN of 4 and 7 μM, respectively.  Since its discovery as an inhibitor of 
membrane trafficking, ONO has become a fixture of “wash-out” studies due to its 
reversible binding.  Fifteen years later, these two inhibitors and a handful of others, 
have been pivotal in demonstrating the importance and ubiquity of phospholipases in 
regulating membrane tubulation and the structure and function of the endomembrane 
system.   
Lysophospholipid acyltransferases 
 The opposing enzymatic activity to that of PLA1 and PLA2 enzymes is provided 
by a diverse group of enzymes that are collectively called LPATs.  Enzymes are 
classified as LPATs if they possess the ability to transfer an acyl chain to a 
lysophospholipid.  They were first described in the 1950s by the researchers Kennedy, 
Weiss, and Lands who uncovered two major systems for phospholipid synthesis and 
remodeling172–174.  The de novo process of phospholipid synthesis from glycerol-3-
phosphate and fatty acids is named the Kennedy pathway and the LPAT mediated 
remodeling of phospholipids has become known as the Lands cycle175,176. 
 The acyltransferases of the Kennedy pathway produce PA with saturated acyl 
chains at both the sn-1 and sn-2 position.  PA is then converted to other phospholipids 
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through the intermediates DAG and cytidine diphospho-DAG (CDP-DAG)177.  However, 
bulk cellular phospholipids contain nearly equal portions of saturated and unsaturated 
acyl chains.  Saturated acyl chains are predominantly in the sn-1 position and 
unsaturated acyl chains are nearly exclusive to the sn-2 position.  The Lands cycle 
maintains the asymmetry of acyl chain saturation in phospholipids through continuous 
PLA2 dependent hydrolysis of the sn-2 acyl chain and LPAT dependent reacylation
172. 
 While the importance of the Kennedy pathway for bulk lipid synthesis has long 
been understood, the significance of the Lands cycle is still being discovered.  The most 
studied aspect of the Lands’ cycle is its role in the potentiation of the inflammatory 
response through polyunsaturated fatty acid derived signaling molecules178,179.  It is also 
important in the production of surfactant in the lungs, embryogenesis and development, 
and the production of apolipoproteins.  Finally, there is a growing understanding that the 
Land’s cycle is important for regulating intracellular membrane trafficking. 
 The first solid indication that LPATs were involved in membrane trafficking 
emerged from studies that utilized a powerful new tool, the small molecule inhibitor CI-
976 (2,2-methyl-N-(2,4,6,-trimethoxyphenyl) dodecanamide).  This molecule is a fatty 
acid anilide derivative designed to mimic fatty acyl-CoA and to inhibit acyl-
CoA:cholesterol acyltransferase in the treatment of heart disease180.  However, CI-976 
possesses only weak inhibitory activity against acyl-CoA:cholesterol acyltransferases, 
but is a strong inhibitor of LPATs.  The utility of this hydrophobic, membrane permeant 
LPAT inhibitor was first discovered during a 2003 screen for the inhibition of Golgi 
associated LPAT activity; CI-976 showed strong inhibition of lysophosphatidylcholine 
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(LPC) and lysophosphatidylethanolamine (LPE) acyltransferase activities181.  Treatment 
of mammalian cells with CI-976 stimulated a remarkable enhancement of Golgi 
membrane tubulation and retrograde trafficking.  This tubulation activity was 
phenotypically similar to BFA induced tubulation, although comparatively delayed.  
Additionally, CI-976-induced Golgi tubulation was inhibited by concomitant PLA2 
inhibition, indicating for the first time that PLA2s and LPATs work in concert to regulate 
the dynamic structure of the Golgi complex182. 
 Like PLA2 enzymes, LPATs are involved in membrane trafficking at the ER and 
endosomes. For example, CI-976 reversibly inhibited a very late step in COPII vesicle 
budding, resulting in the accumulation of secretory cargo at ERESs183.  Interestingly, 
ERESs exhibited Sar1p-dependent membrane tubulation in the presence of CI-976, 
suggesting the involvement of LPAT activity in the fission of COPII budding elements in 
vivo.  CI-976 was also found to stimulate membrane tubule genesis from endosomes 
and to inhibit the recycling of transferrin and transferrin receptors from the endocytic 
recycling compartment, suggesting a role for LPATs in the budding of vesicles from 
endosome tubules184.  The LPAT isoforms inhibited by CI-976 and their roles in 
regulating membrane trafficking are not yet known. 
 The identification and characterization of the human LPATs began in earnest 
about 40 years after Kennedy and Lands seminal work.  This work was pioneered by 
Takao Shimizu and colleagues, who have assayed the substrate specificity of nearly 
every LPAT enzyme, laying the groundwork for a modern understanding of human 
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LPAT biology and the relationships that exist between LPAT enzymes185.  In excess of 
fifteen mammalian LPATs have been identified; they are distributed across the AGPAT, 
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Figure 1-5.  A partial phylogenetic tree of human acyltransferase enzymes 
Adapted from Hishikawa et al211.  
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diacylglycerol acyltransferase 2 (DGAT2), and membrane bound O-acyltransferase 
(MBOAT) gene families (Figure 1-5). 
 Naming conventions for LPATs are a subject of ongoing disagreements, partly 
because of multiple, nearly simultaneous ‘discoveries’ and differences in naming 
conventions between interspecies orthologs.  Complicating matters further, efforts have 
been made to rename LPATs based on their substrate specificity.  Empirical 
determinations of LPAT specificity vary dramatically depending on the assay type, 
experimental conditions, and the LPAT ortholog’s species of origin.  In order to avoid 
potential confusion, herein the naming convention of the NCBI for human genes will be 
followed. 
 Of the three LPAT gene families, the smallest is the DGAT2 family.  DGAT2s are 
specific for primarily diacylglycerol and monoacylglycerol acceptors and have lesser 
activity for lysophospholipid acceptors.  The founding member of the family, DGAT2, is 
a 40-44 kDa integral membrane protein of the ER, with one or two transmembrane 
spans and an active site histidine that primarily synthesizes triacylglycerol (TAG) from 
DAG and acyl-CoA186,187.  It is highly conserved from yeast to humans and is thought to 
be responsible for the bulk of TAG synthesis in most, if not all, tissues.  There is also 
evidence that DGAT2 is inextricably linked to de novo glycerolipid synthesis and the 
sequestration of free fatty acids188,189.  The monoacylglycerol O-acyltransferase 1 
(MOGAT1) and MOGAT2 enzymes synthesize DAG from monoacylglycerol (MAG) and 
acyl-CoA, a key step toward the synthesis of TAG and an activity that is concentrated in 
the small intestine, stomach, kidney, adipose, and liver190,191.  Acyl-CoA wax alcohol 
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acyltransferase 2 (AWAT2) is involved in the synthesis of long chain alcohols (waxes) of 
the skin192.  Little is known about the remaining two DGAT2 family members DGAT2-
like 6 (DGAT2L6) and MOGAT3. 
 The MBOAT family consists of multipass, usually ER-localized enzymes.  The 
family has a very wide range of acyl chain acceptor specificities.  The enzymes DGAT1 
and the sterol O-acyltransferase (SOAT1) and SOAT2 paralogs catalyze the formation 
of TAG from DAG and acyl-CoA and sterol esters from free cholesterol and acyl-CoA.  
They are very important enzymes for the synthesis of neutral lipids destined for lipid 
droplets or apolipoproteins186,193–196.  Despite the similar name and substrate specificity, 
DGAT1 and DGAT2 are not evolutionarily related197.  In a study of hepatic DGAT1 and 
DGAT2 function, DGAT2 was shown to mediate TAG synthesis from glycerol and 
endogenous (saturated) fatty acids, whereas DGAT1 mediated the incorporation of 
exogenous oleic acid into TAG198.  MBOAT1 prefers acylating lysophosphatidylserine 
(LPS) with oleoyl-CoA, MBOAT2 prefers lysophosphatidic acid (LPA) and LPE 
acceptors and oleoyl-CoA donors, LPCAT3 prefers LPC and unsaturated and 
polyunsaturated acyl donors, and MBOAT7 is a lysophosphatidylinositol (LPI) 
acyltransferase with incredible specificity to arachidonoyl acyl donors199.  MBOAT7 has 
been studied by two groups in a mouse knockout model and has been shown to be very 
important for brain development200,201.  MBOAT4 octanoylates the ghrelin peptide and is 
crucial for regulating feeding urges, adiposity, and insulin secretion202.  Porcupine 
(PORCN) palmitoylates Wnt family proteins and is essential for Wnt trafficking to the 
extracellular environment203. 
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 The large AGPAT family has been alternatively known as the LPAAT 
(lysophosphatidic acid acyltransferase) family, though most family members are not 
specific to LPA204,205.  AGPATs are characterized by a conserved amino terminal 
NHX4D motif and a less conserved central EGTR motif, both of which play a role in 
enzymatic activity206,207.  All members are integral membrane proteins; the 
transmembrane topological orientation of AGPAT1 and AGPAT3 isoforms has been 
mapped208,207.  The crystal structure of a chloroplast localized AGPAT from squash 
indicates that acyl chain specificity may be determined by the length and amino acid 
composition of a semi-conserved hydrophobic ‘tunnel’209,210. 
 The AGPAT family contains four enzymes with primarily glycerol-3-phosphate 
acyltransferase (GPAT) activity: GPAT mitochondrial (GPAM), GPAT2, AGPAT9, and 
AGPAT6211.  GPAM is localized to the mitochondrial outer membrane and is 
transcriptionally regulated through insulin and glucose signaling.  Overexpression of 
GPAM results in the net redirection of exogenous oleic acid to TAG in preference to 
phospholipids, suggesting a role in TAG anabolism212,213.  GPAT2 is another 
mitochondrial GPAT but, unlike GPAM, does not seem to be under metabolic 
transcriptional control and is most highly expressed in testis, liver, and brown 
adipose214,215.  AGPAT9 is ER localized, widely expressed, and influenced by PPARγ 
agonists216–218.  AGPAT6 is a widely expressed, ER localized GPAT.  AGPAT6 knock-
out models show that it is essential for lactation and the formation of subcutaneous fat 
stores218–222. 
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 AGPAT1 is an ER localized LPA acyltransferase with broad acyl-CoA 
specificity223.  AGPAT2 is an ER localized LPA acyltransferase that is best known for 
being the gene that is mutated in congenital generalized lipodystrophy (CGL) type 1, 
also known as Berardinelli-Seip Congenital Lipodystrophy.  CGL individuals have a 
remarkable absence of subcutaneous adipose tissue, as well as hyperglycemia and 
hepatic steatosis224–226.  LPCAT4 is an ER localized LPE specific acyltransferase that is 
most highly expressed in the brain.  It prefers long chain saturated and mono-
unsaturated acyl donors, and has broad specificity for lysophospholipid acceptors that, 
as its name suggests, includes LPC but also LPA, lysoPAF, and LPS227.  LPCAT2 is an 
ER and lipid droplet localized LPAT that has dual enzymatic activities for the synthesis 
of PAF from lysoPAF and acetyl-CoA in response to inflammatory signaling and for the 
synthesis of PC from LPC and arachidonoyl-CoA136,228.  LPCAT1 is an ER localized 
LPC acyltransferase with specificity to saturated acyl donors; it plays a crucial role in the 
production of lung surfactant228–233.  Lysocardiolipin acyltransferase 1 (LCLAT1) is a 
mitochondrial enzyme that is responsible for the production of cardiolipid and, to a 
lesser extent, PI234–237.  AGPAT4 is highly expressed in the brain and also in the gut, 
lung, spleen, leukocytes, and adipose; it prefers to acylate LPA238–240.  AGPAT5 is an 
ER and mitochondria localized LPAT with specificity to LPA and LPE; it is most highly 
expressed in the testis237–239.  Lysophosphatidylglycerol (LPG) acyl transferase 1 
(LPGAT1) is ER localized and has a preference for LPG acceptors and saturated, long 
chain acyl-CoA donors241.  TAZ (tafazzin) is a lysocardiolipin specific acyltransferase 
that is localized to the mitochondria.  Mutations in TAZ cause the human disease Barth 
37 
 
syndrome, which is characterized by cardiomyopathy, exercise intolerance, and 
neutropenia242–244. 
 AGPAT3 is a LPA and LPI acyltransferase with strong preference for 
arachidonoyl-CoA239,245,246.  It colocalizes with cis-Golgi, ER, and nuclear envelope 
markers239,245.  Expression is very broad but highest in the testis, liver, and kidney238,246.  
The protein likely contains two transmembrane domains, the first of which bisects 
cytoplasmic NHX4D and luminal EGTR catalytic motifs
207.  Its enzymatic activity is 
important for the regulation of Golgi complex structure and function, including 
membrane tubule formation.  When AGPAT3 is overexpressed, the formation of Golgi 
membrane tubules is inhibited.  Knockdown of AGPAT3 accelerates both anterograde 
and retrograde protein trafficking and leads to Golgi fragmentation245. 
 Overexpression of AGPAT3 counteracts the tubule-inducing effects CI-976, 
suggesting that AGPAT3 is a target of the drug. However, it is possible that another 
LPAT also contributes to Golgi membrane remodeling because CI-976 has been shown 
to inhibit Golgi localized LPC and LPE acyltransferase activity.  Alternatively, Golgi 
localized LPC and LPE acyltransferase activity could be the consequence of the 
remodeling of AGPAT3 generated PA into DAG by PA phosphatase, followed by 
conversion to PC and PE by Golgi localized cholinephosphotransferase and 
phosphoethanolamine transferase (Figure 1-6)245,247,248. 
 The LPAT antagonist CI-976 has been shown to inhibit COPI vesicle formation, a 
process whose molecular mechanism is the focus of a recent study by Hsu and 
colleagues71.  A model incorporating their findings, together with the findings from other 
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Figure 1-6.  Pathways of lipid remodeling 
Enzymatic pathways which lead to the modification and interconversion of lipid species. 
Sphingomyelin (SM); ceramide (Cer); PI 4-phosphate (PI4P); PI-4,5-phosphate 
(PI4,5P); DAG kinase (DAGK); PA phosphatase (PA P'tase); PC specific phospholipase 
C (PC-PLC); PI specific PLC (PI-PLC); SM synthase (SMS).  Adapted from Ha et al248. 
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labs, is shown in Figure 1-7.  In an in vitro COPI budding assay using purified Golgi 
membranes and cytosol, COPI coatomer subunits and Arf1 are required for both vesicle 
and membrane tubule formation.  Ablation of AGPAT3 activity by addition of CI-976 or 
AGPAT3 specific antibody decreased COPI budding and concomitantly increased 
membrane tubule formation.  The addition of pharmacological PLA2 inhibitors or anti-
cPLA2α antibody increased vesicle formation and decreased tubule formation.  The 
opposite effect was observed when purified cPLA2α was added to the assay. 
 Examination of endogenous cPLA2α and AGPAT3 by immunofluorescence 
microscopy shows colocalization with endogenous coatomer proteins.  The α-COP 
coatomer subunit was shown by immuno-EM to localize to the base and tip, but not the 
length, of membrane tubules.  They propose that Arf1 and COPI coatomer recruitment 
initiates bud formation and that buds mature into either vesicles or membrane tubules, 
depending on the balance of cPLA2α and AGPAT3 activity. 
 AGPAT3 generates PA, a negative membrane curvature inducing phospholipid, a 
recruiter of COPI coatomer subunits, and a recruiter of BARS, which mediates COPI 
vesicle fission125,131.  Through these mechanisms, AGPAT3 is thought to stimulate COPI 
vesicle budding and scission.  cPLA2α generates LPC, a positive membrane curvature 
inducing phospholipid that stabilizes budding vesicles and membrane tubules.  Thus 
cPLA2α activity is important for both vesicle and membrane tubule biogenesis, but 
unbalanced cPLA2α activity primarily leads to increased membrane tubulation.  The final 
step of COPI vesicle fission requires the conversion of PC to PA by PLD273. 
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 Hsu and colleagues also assert that the biogenesis of all Golgi membrane 
tubules is initiated as COPI buds, however they do not attempt to reconcile this 
assertion with the mechanisms of COPI independent membrane tubulation.  The model 
presented in Figure 1-7G argues that COPI independent membrane tubulation is the 
product of phospholipase activity.  In the absence of COPI vesicle formation, which 
normally acts to consume membrane extensions, cPLA2α activity maintains long, stable, 
membrane tubules. 
 The above studies demonstrate that a complex relationship exists between 
vesicle coat components, phospholipases, LPATs, and the myriad accessory proteins 
that regulate the formation of membrane vesicles and tubules.  This dissertation 
addresses these issues by focusing on how lipid remodeling by phospholipases and 
LPATs affects membrane trafficking.  I will examine the relationship between 
phospholipases and AGPAT3 in Chapter 2, the importance of LPATs in secretion in 
Chapter 3, the transmembrane topology of LPCAT3 in Chapter 4, and the importance of 
LPCAT3 activity for the regulation of membrane trafficking in Chapter 5. 
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Figure 1-7.  Mechanisms of cPLA2α and AGPAT3 mediated membrane 
deformation 
Models of cPLA2α and AGPAT3 activity as it contributes to COPI vesicle and Golgi 
membrane tubule formation. (A) Flat membrane that will be modified by 
curvature inducing proteins; (B) Arf1 and coatomer binding deforms membranes, 
initiating the first steps of vesiculation or tubulation; (B to C) AGPAT3 activity produces 
unsaturated PA, a lipid that resists positive curvature; (B to D) cPLA2α activity produces 
LPC, a positive curvature and membrane tubule stabilizing lipid; (C and D to E) LPC 
stabilizes positive curvature of the bud and unsaturated PA stabilizes negative 
curvature at the bud neck; (F) The concerted PA production activities of AGPAT3 and 
PLD2 at the bud neck help to recruit BARS and aid vesicle fission; (G) PLA2 activity 
can produce membrane curvature and tubulation in the absence of Arf1 and coatomer.  
Reproduced from Ha et al248. 
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CHAPTER TWO:  Regulation of Golgi function by AGPAT3 and PLA 
enzymes 
Introduction 
 The membrane dynamics and structure of the Golgi complex are regulated, in 
part, by the activity of LPATs and phospholipases171,183,184,249,250.  The strongest 
evidence for the involvement of LPATs in Golgi membrane trafficking comes from 
studies which show that the LPAT inhibitor CI-976 induces Golgi membrane tubulation 
and recycling to the ER181.  Also, studies of the LPAT enzyme AGPAT3 show that 
overexpression or knockdown affects Golgi morphology and membrane dynamics245. 
 A great deal of evidence has been collected to support the role of 
phospholipases in regulating Golgi membrane dynamics.  PLA2 inhibitors (e.g. BEL, 
ONO-RS-082) and agonists (e.g. melittin) have profound effects on membrane 
trafficking148.  The phospholipase PAFAH IB induces Golgi membrane tubule formation 
in an in vitro reconstitution system and when overexpressed in mammalian cells; its 
knockdown induces Golgi fragmentation110.  The phospholipase iPLA1γ mediates 
retrograde transport from the Golgi complex and its knockdown delays BFA-mediated 
Golgi recycling and cholera toxin B retrograde trafficking168.  The phospholipase cPLA2α 
hydrolyzes arachidonic acid from Golgi phospholipids and induces the formation of 
membrane tubules in response to secretory load101,251,252.  Overexpression of cPLA2α 
can lead to Golgi fragmentation and decreases the rate of anterograde transport253.  
 While the roles of LPATs and PLA2s have been studied in isolation, there has 
been little progress toward an integrated model of LPAT and phospholipase activity as 
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they affect Golgi membrane structure and dynamics.  It is likely that there are 
unappreciated antagonistic and/or synergistic relationships between these classes of 
enzymes because their activities are, broadly speaking, opposite.  The mechanisms and 
prevalence of LPAT-PLA2 functional relationships will vary depending on the relevant 
enzyme isoforms, tissue/cell-type, and experimental conditions. 
 The mechanisms of AGPAT3 and phospholipase enzyme localization and 
substrate availability will be the primary focus of these experiments.  The trafficking of a 
bolus of secretory cargo is known to stimulate membrane binding of phospholipases 
and stimulate their activity, often in combination with transiently increased Ca2+ 
concentrations101,166.  AGPAT3 is limited by substrate availability, but other transient 
regulatory mechanisms have yet to be discovered.  Production of PA by AGPAT3 
activity is thought to help recruit COPI coatomer248.  It is possible that AGPAT3 
localization and activity is also regulated in response to membrane trafficking events. 
 AGPAT3 and phospholipases may have an antagonistic relationship if they are 
colocalized and have complementary substrate and product specificities, as their net 
activities would not be expected to alter total PA or LPA concentration.  Antagonism 
might also be seen with phospholipases that hydrolyze other phospholipids.  All 
lysophospholipids induce positive membrane curvature to a much greater extent than 
their corresponding phospholipids, which would counteract negative curvature induced 
by AGPAT3 derived PA.   
 Synergy between colocalizing AGPAT3 and phospholipases could occur if their 
lipid products influence two independent aspects of the same process, for instance 
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lysophospholipid stabilization of the positive curvature of a budding COPI vesicle and 
PA stabilization of the negative curvature at the bud neck in COPI budding (Figure 1-7 
E, F).  By this mechanism, even phospholipases that hydrolyze PA could be synergistic 
with AGPAT3 as their complimentary activities would resupply their substrates. 
 In this chapter, I present an investigation of these topics in the context of 
mammalian overexpression and co-overexpression of AGPAT3 and three PLA 
enzymes. 
Materials and methods 
Plasmids 
GFP-tagged AGPAT3 and HA-tagged PAFAH IB expression plasmids were constructed 
as previously described110,245.  The GFP-tagged cPLA2α expression plasmid was a kind 
gift from Victor Hsu.  FLAG-tagged iPLA1γ expression plasmid was a kind gift from 
Hiroki Inoue.167 
Cell culture 
HeLa cells and transformed bovine testicular cells (BTRD) were grown and maintained 
in minimal essential medium (MEM) supplemented with 10% Fetal Bovine Serum (FBS) 
and 1% penicillin/streptomycin at 37°C in 95% humidity and 5% carbon dioxide (CO2). 
Immunofluorescence 
Cells were transfected in 35 mm2 culture dishes using polyethylenimine (PEI) from 
Polysciences Inc. or Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to 
manufacturer’s instructions.  Transfection was performed using 1 μg DNA and 5 μg 
PEI/2.5 μl Lipofectamine for the 24 h prior to experiments.  Cells were grown on glass 
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coverslips and fixed with 3.7% formaldehyde in phosphate buffered saline (PBS), 
washed 3 times in PBS, and permeabilized with 0.1% Triton X-100 in PBS.  Cells were 
incubated with primary antibodies for 1 h at room temperature using the manufacturer’s 
recommended dilution, washed 3 times, treated identically with secondary antibodies, 
and mounted on glass slides with VectaShield (Vector Laboratories).  Cells were viewed 
and imaged using a Perkin-Elmer Ultraview spinning disk confocal microscope at 100X.  
Image analysis was performed using the ImageJ software package (NIH, Bethesda, 
MD) or the FIJI distribution of ImageJ254.  Rabbit anti-GPP130 (Covance), mouse anti-
HA (Covance), and FITC/TRITC/Cy5 conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratories and Invitrogen) were used for immunofluorescence (IF).   
BFA and CI-976 assays 
Cells were washed three times with 37°C MEM (without FBS) followed by incubation 
with 2.5 μg/ml Brefeldin A (Endo Life Sciences or Sigma-Aldrich) or 50 μM CI-976 
(Tocris, Ellisville, MO) at 37°C.  In BFA washout experiments, BFA was incubated with 
HeLa cells for 20 min and with BTRD cells for 15 min, cells were washed 3 times with 
37°C MEM containing FBS and then returned to a 37°C incubator.  Scoring for intact 
Golgi complexes was performed by visual inspection under a mercury lamp at 100X; 
cells were categorized as having ‘intact’ Golgi complexes only if GPP130 was not 
dispersed, fragmented, or partially ER localized.  Error bars are SEM.  Significance 
determined by paired Student’s t-test. 
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Results 
AGPAT3 or PLA overexpression does not disrupt the Golgi 
 Golgi morphology is established through vesicle and tubule dependent processes 
that balance anterograde and retrograde trafficking, maintain the integrity of the Golgi 
ribbon, and establish cisternal identity through the partitioning of resident enzymes.  
AGPAT3 and PLAs influence Golgi vesicle and tubule dynamics, therefore I began my 
investigation with an assessment of Golgi morphology in AGPAT3 and PLA 
overexpressing cells.  The morphology of the Golgi complex was scored as ‘intact’ or 
‘not intact’ by IF using anti-GPP130 as a Golgi marker.  Increased peripheral staining 
was observed in PAFAH IB overexpressing cells, but Golgi morphology was not 
significantly disrupted under this or any other expression condition (Figure 2-1). 
Golgi reformation following BFA washout is accelerated by AGPAT3, iPLA1γ, and 
cPLA2α overexpression 
 To investigate possible relationships between AGPAT3 and PLA enzymes in 
Golgi membrane dynamics, I examined the reassembly of the Golgi complex following 
BFA washout in HeLa cells overexpressing AGPAT3 and/or a PLA enzyme.  Compared 
to control cells expressing GFP, all cells expressing AGPAT3 or a PLA enzyme showed 
accelerated Golgi complex reformation (Figure 2-2).  The combination of AGPAT3 and 
PAFAH IB accelerated Golgi reformation by a rate that is intermediate to that of 
AGPAT3 or PAFAH IB alone.  Co-overexpression of AGPAT3 and iPLA1γ accelerated 
Golgi reformation to a greater extent than either enzyme individually. 
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Figure 2-1.  Steady state Golgi morphology 
AGPAT3 and PLA overexpression did not significantly affect steady state Golgi 
morphology of HeLa cells.  (n=3) 
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Co-overexpression of AGPAT3 and cPLA2α also accelerated Golgi reformation to a 
greater extent than does either enzyme alone. 
 A similar BFA washout experiment was performed in BTRD cells.  BTRD cells, a 
bovine testicular cell line, were used due to their generally large and well-formed Golgi 
apparatus that undergoes dramatic tubulation events amenable to live cell microscopy.  
While the expression of AGPAT3 has not been experimentally confirmed for these cells, 
it should be noted that in one study of AGPAT3 expression in 18 tissues, the highest 
expression level was found in testicular tissue239. 
 The Golgi reassembly experiment showed cPLA2α was even more effective at 
accelerating Golgi reformation than it was in HeLa cells (Figure 2-3).  AGPAT3 did not 
significantly accelerate Golgi reformation in BTRD cells, in contrast to the acceleration 
observed in HeLa cells.  The combination of cPLA2α and AGPAT3 had an intermediate 
phenotype to the individually expressed enzymes. 
AGPAT3 and cPLA2α do not “interact” in the regulation of Golgi recycling 
 Under normal conditions, the Golgi complex undergoes COPI vesicle and 
membrane tubule mediated retrograde trafficking, or recycling, to the ERGIC and ER.  
This process can be greatly exaggerated by treatment with BFA or CI-976, which allows 
for the measurement of recycling kinetics.  AGPAT3 overexpressing HeLa cells have 
been shown to have slowed Golgi recycling to the ER245.  It is possible that cPLA2α 
could “interact” with AGPAT3 to perturb Golgi recycling.  This possibility was tested in 
by inducing Golgi recycling using either BFA or CI-976 treatment of BTRD cells 
overexpressing AGPAT3 and cPLA2α. 
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Figure 2-2.  Golgi reassembly in HeLa cells during BFA washout 
AGPAT3 and PLA overexpression accelerated Golgi reformation during BFA washout.  
HeLa cells were treated with BFA for 20 min, washed three times, fixed 1-2 h after 
washout, and stained for endogenous GPP130.  GFP+iPLA1γ, AGPAT3, and 
AGPAT3+iPLA1γ have significantly more intact Golgi than control cells expressing GFP 
alone. (n=4, * p<0.05) 
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Figure 2-3.  Golgi reassembly in BTRD cells during BFA washout 
AGPAT3 and cPLA2α overexpression accelerated Golgi reformation during BFA 
washout.  BTRD cells were treated with BFA for 15 min, washed three times, and fixed 
55 min after washout.  The Golgi marker was endogenous GPP130.  cPLA2α 
significantly accelerated Golgi reformation. (n=5, * p<0.05) 
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 BFA treatment of BTRD cells induced Golgi recycling to the ER over ~12 min 
(Figure 2-4).  Golgi recycling kinetics were not significantly different in cells 
overexpressing AGPAT3, cPLA2α, or both AGPAT3 and cPLA2α. 
 CI-976 is a broad inhibitor of AGPAT activity that stimulates Golgi membrane 
tubulation and recycling to the ER184.  Golgi recycling induced by CI-976 was slowed in 
cPLA2α overexpressing cells (Figure 2-5).  AGPAT3 overexpression did not affect CI-
976 induced Golgi recycling rates and the co-overexpression of AGPAT3 and cPLA2α 
had an intermediate phenotype. 
Discussion 
 These experiments were performed in order to integrate AGPAT3 and PLA 
activity into a model of Golgi membrane dynamics and phospholipid remodeling.  The 
results confirm that AGPAT3 and PLA activity is important for these processes and 
suggests synergy between AGPAT3 and iPLA1γ to accelerate Golgi reformation.  
Evidence for antagonism between AGPAT3 and cPLA2α activity was seen in Golgi 
reformation as well as Golgi recycling to the ER. 
Steady state Golgi morphology 
 Golgi morphology was not grossly disrupted by the overexpression of AGPAT3 or 
the tested PLAs (Figure 2-1).  Not surprisingly, co-overexpression of AGPAT3 and PLA 
enzymes also did not significantly alter Golgi morphology.  The lack of effects could be 
due to various reasons including mechanisms to compensate for overexpression, 
inability to significantly change the lipid composition in vivo, or in the case of co-
overexpression, compensatory increases in rivaling enzyme activities. 
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Figure 2-4.  Golgi recycling during BFA treatment 
BTRD cells were incubated with 2.5 μg/ml BFA and analyzed by anti-GPP130 IF for 
recycling to the ER.  AGPAT3 and cPLA2α overexpression did not affect Golgi recycling 
during BFA treatment.  (n=3) 
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Figure 2-5.  Golgi recycling during CI-976 treatment 
BTRD cells were incubated with 50 μM CI-976 for 35-45 min and analyzed by anti-
GPP130 IF for Golgi recycling to the ER.  cPLA2α overexpression significantly slows 
Golgi recycling.  (n=3, * p<0.05) 
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Golgi reformation during BFA washout 
 Golgi reformation during BFA washout relies on COPII and COPI vesicle 
transport and membrane tubulation.  During BFA treatment, COPI vesiculation is 
inhibited, which causes the Golgi complex to recycle to the ER and form a contiguous 
ER-ERGIC-Golgi membrane network.  To a large extent, Golgi, ERGIC, and ER 
markers all partition within this membrane network.  When BFA is washed out of the 
system, COPI budding is restored and membrane trafficking begins to return to normal.  
A combination of COPII and COPI budding from the ER-ERGIC-Golgi network 
eventually reestablishes independent Golgi, ERGIC, and ER compartments.  The 
reforming Golgi is initially fragmented into ‘mini-stacks’ that then merge into a single 
network by the action of membrane tubule connections.  Due to the influence of COPII, 
COPI, and membrane tubulation on Golgi reformation, this assay is excellent for 
identifying abnormalities in these processes.  However, due to the confluence of 
processes in Golgi reformation, this assay is poorly suited to characterizing the 
molecular mechanisms of membrane trafficking. 
 AGPAT3 activity has been shown to promote COPI budding and decrease 
membrane tubule formation73,245.  One would predict that AGPAT3 overexpression 
accelerates the COPI dependent formation of Golgi mini-stacks, but may slow the 
membrane tubule dependent interconnection of mini-stacks.  cPLA2α promotes Golgi 
membrane tubulation which is expected to be important for mini-stack interconnection.  
iPLA1γ overexpression has previously been shown to favor membrane tubulation, an 
activity that could accelerate the reconnection of Golgi mini-stacks167.   
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 The study of Golgi reformation following BFA washout in HeLa cells (Figure 2-2) 
showed that AGPAT3, iPLA1γ, and cPLA2α accelerated Golgi reformation.  Co-
overexpression of AGPAT3 with a PLA further accelerated Golgi reformation.  These 
results are evidence that AGPAT3 and PLAs synergistically accelerate Golgi 
reformation.  
 When Golgi reassembly was examined in a different cell type, BTRD cells, 
cPLA2α significantly accelerated Golgi reformation but AGPAT3 only very slightly 
accelerated reformation.  In co-overexpressing cells, the phenotype was intermediate to 
that of separately overexpressing cells.  BTRD cells are expected to have high AGPAT3 
expression, therefore it is unclear what can be concluded from these results.  One 
possible conclusion is that very high AGPAT3 activity is antagonistic of cPLA2α activity 
during Golgi reformation. 
 To better understand the mechanisms that mediate synergistic and antagonistic 
relationships between AGPAT3 and PLA activity, more targeted assays are required.  In 
vitro assays (COPI budding, COPII budding, Golgi tubulation) would be the most 
specific and are feasible using purified Golgi from overexpressing cells. 
Golgi recycling to the ER 
 Golgi membranes recycle to the ER by COPI vesicles and membrane tubules.  
Treatment of cells with BFA or CI-976 induces extensive Golgi tubulation, decreases 
COPI vesiculation, and merges the Golgi with the ER. 
 To determine if AGPAT3 and cPLA2α have synergistic or antagonistic effect on 
tubule mediated recycling of the Golgi to the ER, BTRD cells overexpressing these 
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enzymes were treated with either BFA or CI-976 and scored for Golgi disruption.  No 
statistically significant differences were observed in BFA treated cells, contradicting a 
previously published report of slowed Golgi recycling in AGPAT3 overexpressing HeLa 
cells245.  The small size of the BTRD data set my be preventing the observation of a 
weak inhibition of Golgi recycling, however it is possible that BTRD and HeLa cells have 
different characteristics in this assay. 
 The inhibition of LPAT activity by CI-976 treatment has a number of 
consequences on membrane trafficking, including halting COPII budding from the ER, 
COPI budding from the Golgi, and the induction of Golgi membrane tubulation, followed 
by eventual fusion of the Golgi with the ER. 
 It has been previously reported that cPLA2α stabilized the Golgi by promoting the 
formation of intra-cisternal membrane tubules and that AGPAT3 increased Golgi 
stability by inhibiting the formation of CI-976 induced retrograde membrane tubules73,245.  
The CI-976 Golgi recycling experiment reported here supports these previous results.  
cPLA2α stabilized the Golgi during CI-976 treatment and AGPAT3 overexpression 
slightly increased Golgi stability.  Co-overexpression of AGPAT3 and cPLA2α had an 
intermediate phenotype to separately overexpressing cells, indicating possible 
antagonism between their activities. 
 AGPAT3 and cPLA2α activity was found to be antagonistic during CI-976 induced 
Golgi recycling and Golgi reformation following BFA washout.  Immediately following the 
completion of these experiments, Victor Hsu and colleagues published a remarkably 
relevant report detailing antagonism between AGPAT3 and cPLA2α activity
73.  They 
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showed that AGPAT3 and cPLA2α colocalize at COPI budding sites, where AGPAT3 
activity promotes vesiculation at the expense of membrane tubulation, while the 
opposite is true of cPLA2α.  Given this additional evidence, it is very likely that these 
enzymes have antagonistic activities that regulate Golgi membrane dynamics.  One 
caveat to this model is that the experimental conditions under which antagonism is 
observed, expression/activity levels were altered.  In untreated cells, balanced AGPAT3 
and cPLA2α activity could have a synergistic effect to promote efficient COPI 
vesiculation (Figure 1-7 E,F). 
However, it has also been reported that cPLA2α and AGPAT3 colocalize to COPI 
budding sites and where their activities may be either antagonistic or synergistic73. 
 Further investigation of synergistic and antagonistic relationships between LPAT 
and phospholipase activity is likely to prove fruitful.  However, there are a great number 
of possible combinations of LPATs and phospholipases; too large for an exhaustive 
screen.  It may be better to search for interactions with a single LPAT (as done here) or 
phospholipase or to use broad specificity inhibitors. 
59 
 
CHAPTER THREE:  Screening for the involvement of LPATs in 
membrane trafficking 
Introduction 
 There are at least 15 enzymes from the AGPAT, MBOAT, and DGAT2 gene 
families that are suspected to have lysophospholipid acyltransferase activity136,185.  
Previous studies using chemical inhibitors (CI-976) have strongly suggested that 
multiple LPATs play roles in regulating intracellular membrane trafficking181,183,255.  To 
determine which LPAT enzymes play a significant role in regulating membrane 
trafficking, I screened cells overexpressing a set of LPAT enzymes for changes in 
secretion.  The secretion phenotype is an excellent measure of membrane trafficking 
disruption because secretory cargo transport starts in the ER and relies on the efficient 
function of several other organelles (ERGIC, Golgi, TGN) and trafficking intermediates 
(COPII, AP/clathrin coated vesicles).  A defect at any of these steps would disrupt 
trafficking. 
 The screening assay measured the extracellular concentration of an 
overexpressed enzyme that was secreted by ‘bulk flow’, horseradish peroxidase 
(ssHRP/HRP) fused to the secretory signal sequence of human growth hormone.  If the 
secretion of ssHRP was significantly altered by the co-overexpression of an LPAT 
enzyme, it suggests a significant alteration of the pathways responsible for the 
trafficking of soluble secreted cargo proteins.  Due to the integrated nature of 
membrane trafficking, it is likely that disrupted secretion will be accompanied by the 
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alteration of other membrane trafficking pathways.  One LPAT enzyme was selected for 
additional characterization, which will be the focus of Chapters 4 and 5. 
Materials and methods 
Plasmids 
GFP-tagged AGPAT3 expression plasmid was constructed as previously described245.  
AGPAT4, AGPAT5, and AGPAT6 GFP tagged expression constructs were a kind gift 
from John Schmidt.  AGPAT1, MBOAT1, MBOAT2, MBOAT7, LPCAT3, and LPCAT4 
cDNAs were cloned into pEGFP-C2 (Clonetech) as described on Table 3-1. 
Cell culture and HRP assay 
HeLa cells were grown and maintained in MEM supplemented with 10% FBS and 1% 
penicillin/streptomycin at 37°C in 95% humidity and 5% CO2.  Cells were transfected in 
35 mm2 culture dishes using PEI from Polysciences Inc. according to the manufacturer’s 
instructions.  Transfection was performed using 2 μg DNA (1 μg of ssHRP and 1 μg of 
LPAT/GFP) and 5 μg PEI for the 24 h prior to experiments.  To perform the HRP 
secretion assay, cells were washed three times in MEM without FBS and then 
incubated in MEM containing 3% FBS.  Every hour for 5 h, 100 μl of media was 
removed and placed on ice.  In a 96-well plate, 50 μl of TMB chromogenic reagent 
(Pierce) was added to duplicate 10 μl media samples, the reaction allowed to proceed 
until saturation, halted by the addition of 50 μl 1 M sulfuric acid, and absorbance 
measured at 450 nm.  Error bars are SEM. 
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Table 3-1.  Plasmid construction 
Gene 
Sequence Supplier Sense Primer 
Restriction 
Enzymes 
AGPAT1 BC090849 
Open 
Biosystems 
5' GGATGAATTCATGGATTTGTGGCCAGGG 
EcoRI-KpnI 
3' GGTAGGTACCTTATCCCCCAGGCTTCTTCAGA 
MBOAT1 BC150652 
Life 
Technologies 
5' GGATAGATCTCGATGGCAGCAGAGCCAC 
BglII-BamHI 
3' CCTAGGATCCCTTAGTCGGTCTTCCTCTTGTTGATAG 
MBOAT2 BC016005 
Open 
Biosystems 
5' GGATAGATCTCGATGGCCACCACCAGCA 
BglII-KpnI 
3' GGTAGGTACCTTACTGCTTTAGTGATGAATGTCTCGA 
MBOAT7 BC003164 
Open 
Biosystems 
5' GGATGAATTCATGTCGCCTGAAGAATGGAC 
EcoRI-BamHI 
3' CCTAGGATCCCTTACTCCTCCCGGAGCTTCT 
LPCAT3 BC065194 
Open 
Biosystems 
5' GGTAGGTACCGCATGGCGTCCTCAGCGG 
KpnI-BamHI 
3' CCTAGGATCCCTTATTCCATCTTCTTTAACTTCTCTTTCCTT  
LPCAT4 BC092463 
Open 
Biosystems 
5' GGATGAATTCATGAGCCAGGGAAGTCCG 
EcoRI-KpnI 
3' GGTAGGTACCTTAGTCTCCCTTCTGCTTGGG 
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Fluorescence microscopy 
Cells were grown on glass coverslips and fixed with 3.7% formaldehyde in PBS, 
washed 3 times in PBS, and mounted on glass slides with VectaShield (Vector 
Laboratories).  Cells were viewed and imaged using a Perkin-Elmer Ultraview spinning 
disk confocal microscope at 100X.  Image analysis was performed using the ImageJ 
software package (NIH, Bethesda, MD) or the FIJI distribution of ImageJ254. 
Phylogenetic tree 
Consensus coding sequences from NCBI’s CCDS database were aligned using Clustal 
Omega with default parameters256,257.  The resulting guide tree was plotted with the 
PHYLIP 3.67 drawgram tool258. 
Results 
LPAT intracellular localization 
 The enzymes tested were taken from the AGPAT and MBOAT gene families so 
as to obtain at least one representative LPAT from each major branch of the AGPAT 
phylogenetic tree and all suspected MBOAT LPATs (Figure 3-1).  N-terminal GFP 
fusion constructs were overexpressed in HeLa cells and analyzed by fluorescent 
microscopy to determine localization (Figure 3-2).  All LPATs exhibited a similar, 
primarily ER localization; colocalization with ER markers was confirmed for LPCAT3 
(Figure 3-3)259.  AGPAT3 partially localized to the Golgi complex, as previously reported 
by Schmidt et al.245.  In addition, AGPAT1, AGPAT6, MBOAT1, MBOAT7, and LPCAT3 
showed a propensity to form large puncta or karmellae-like structures (Figure 3-2 and 
Figure 3-3).  Karmellae are poorly understood ER structures consisting of closely 
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Figure 3-1.  LPAT phylogenetic trees 
A)  Phylogenetic tree of selected human AGPAT family enzymes.  B)  Phylogenetic 
tree of human MBOAT family enzymes. 
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Figure 3-2.  LPAT overexpression 
A)  Localization, karmellae-like structures, and conserved domains of tested AGPAT 
enzymes.  The green box indicates the location of the conserved acyltransferase 
domain (pfam01553 as per the NCBI’s Conserved Domain Database).  B)  Localization, 
karmellae-like structures, and conserved domains of tested MBOAT enzymes.  The 
yellow box indicates the conserved MBOAT domain (pfam03062). 
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Figure 3-3.  ER localization of LPCAT3 
Overexpressed GFP-LPCAT3 colocalizes with endogenous p61 and P450.  Note that 
p61, a chaperone that participates in disulfide bond formation259, colocalizes with 
LPCAT3 in karmellae-like structures, while P450 does not. 
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opposed membrane stacks or whorls.  Their biogenesis is not an uncommon response 
to the overexpression of transmembrane proteins and they are not inherently 
detrimental to the cell260.   
LPAT overexpression alters secretion 
 The effect of LPAT co-overexpression on ssHRP secretion varied widely 
between LPAT isoforms (Figure 3-4).  The greatest reduction was seen in the MBOAT7 
overexpression condition (7% of control).  Overexpression of AGPAT1, AGPAT3, 
AGPAT4, MBOAT1, and LPCAT3 significantly reduced ssHRP secretion by very similar 
amounts, to between 20-30% of control.  In notable contrast to these LPATs, 
overexpression of AGPAT5 significantly increased the amount of ssHRP secretion.  
Finally, overexpression of AGPAT6, MBOAT2, and LPCAT4 had no appreciable effect 
on ssHRP secretion.  These changes were independent of expression levels, as 
determined by western blotting against GFP (data not shown). 
Discussion 
 Except in one case, AGPAT5, it appears that LPAT overexpression slows ssHRP 
secretion.  LPAT enzymes are generally ER localized and may regulate ER export 
directly.  However, their phospholipid products are mobile and may disrupt secretion at 
any point along the secretory system.  Mechanisms by which LPATs and lipid 
remodeling could inhibit secretion are discussed in the following contexts: perturbation 
of lipid homeostasis, disruption of COPII function, and induction of the UPR. 
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Figure 3-4.  HRP secretion as affected by LPAT co-overexpression 
ssHRP and an LPAT were co-overexpressed for 5 h and the media tested for HRP 
activity.  Values are normalized to an ssHRP and GFP co-overexpressing condition.  
(n=3) 
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Lipid imbalance 
 The primary function of LPAT enzymes is to remodel membrane 
lysophospholipids into phospholipids.  To delineate the possible consequences of LPAT 
activity on ssHRP secretion, the substrate specificity of the tested enzymes will be 
discussed.  For additional isoform specific details, please see the accompanying 
references. 
 First, consider the enzymes that acylate LPA to form PA.  These are AGPAT1223, 
AGPAT373,245,248, AGPAT4238,239,261, and AGPAT5238,239, which altered HRP secretion to 
30%, 23%, 39%, and 276% of control, respectively.  Due to PA’s small head group, 
negative charge, and strong interactions with Ca2+, it can induce dramatic changes in 
membrane structure that are important for some fission and fusion events262–265.  PA 
can also recruit secondary effector proteins to facilitate membrane trafficking events266–
268.  However, it is possible that these PA-dependent membrane trafficking mechanisms 
are not important at the ER, at least under normal conditions.  PA concentrations in the 
ER are kept very low due to rapid metabolism by enzymes of the Kennedy pathway to 
DAG, PC, and PE177,269,270.  While overexpression of PA synthesizing LPATs may have 
elevated PA concentrations sufficiently to directly regulate membrane trafficking, it is 
just as likely that secretory defects were due to the increased synthesis of PA-derived 
lipids.  Note that AGPAT5, unlike any other LPAT that was tested, is involved in 
mitochondrial lipid synthesis and localizes to a specialized ER domain called the 
mitochondrial-associated membrane264,268,271,272.  The increased secretion of AGPAT5 
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overexpressing cells may be related to increased mitochondrial health and energy 
generation. 
 AGPAT6 is an ER localized GPAT that catalyzes the addition of saturated and 
unsaturated acyl-CoA to glycerol 3-phosphate to produce LPA.  Its activity is important 
for triglyceride metabolism but has little effect on membrane phospholipid composition 
or membrane trafficking218–222.  These previous reports are in agreement with the 
observation that APGAT6 overexpression did not dramatically alter HRP secretion (74% 
of control). 
 MBOAT1 strongly reduced HRP secretion.  It is an ER localized LPAT that 
prefers acylating LPS and LPE with oleoyl-CoA199,261.  As the most abundant anionic 
phospholipid in mammalian cells, PS has important roles in membrane trafficking273.  
PS localization is the most asymmetric of all phospholipids; it is present on the luminal 
side of the ER and Golgi as well as the cytosolic side of the trans-Golgi network, 
endosomes, and plasma membrane274.  PS mediates the localization and activity of a 
variety of proteins, among them protein kinase C, synaptotagmin, Ras and Rho-family 
GTPases and Cdc4216,275,276.  PS has been shown to be essential for retrograde 
trafficking through recycling endosomes/early endosomes277.  It is possible that an 
overabundance of PS could disrupt the localization and activity of enzymes that interact 
with PS.  For instance, there are two classes of TGN derived secretory vesicles 1) a 
clathrin-coated vesicle that is enriched in PS and 2) a vesicle that is poor in PS and 
clathrin.  Increased PS concentrations could enrich the population of clathrin-coated 
vesicles at the expense of other anterograde vesicles278. 
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 MBOAT2 and LPCAT4 have very similar substrate specificities and effects on 
HRP secretion; both enzymes prefer to acylate LPE and decreased HRP secretion to 
85% and 84% of control, respectively199,227,261,279. 
 MBOAT7 overexpression decreased ssHRP secretion to a greater extent than 
did any other LPAT.  MBOAT7 is a LPI acyltransferase with incredible specificity to AA 
acyl-CoA donors, though a mouse knockout model suggests MBOAT7 may also 
possess LPC and LPE acyltransferase activity199,201,280.  In mammals, the majority of PI 
contains polyunsaturated acyl chains (AA, linoleic acid, etc.) at the sn-2 position and it is 
suspected that MBOAT7 is responsible for most of their synthesis201,281.  PI is a 
precursor to the synthesis of phosphatidylinositol phosphates (PIPs), a class of lipids 
that are incredibly important for the regulation of membrane trafficking.  It is likely that 
overexpression of MBOAT7 increases the concentration of PI, which may lead to 
increased synthesis of phosphatidylinositol phosphate (PIP) species.  PIP regulated 
enzymes are too numerous to describe here, but their misregulation would invariably 
cause membrane trafficking defects.  For a detailed discussion of the biology of PI, 
PIPs, and their acyl chains, please see D’Souza and Epand’s recent review282. 
 LPCAT3 overexpression strongly inhibited ssHRP secretion.  A detailed 
discussion of LPCAT3 lipid remodeling and its effects on membrane trafficking is 
reserved for Chapter 5. 
Disruption of COPII trafficking 
 ER export of soluble proteins, such as ssHRP, is dependent on efficient cargo 
loading, budding, and scission of COPII vesicles from ERES.  LPAT enzyme 
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overexpression could, by direct interaction or through lipid remodeling, disrupt the 
localization of components that are critical for efficient COPII vesicle formation.  For 
example, the LPAT inhibitor CI-976 inhibits a late stage in the formation of COPII coated 
vesicles183.  LPAT overexpression sometimes leads to karmellae formation, though the 
mechanisms and physiological implications of karmellae formation are not well 
understood, their presence indicates abnormal ER membrane dynamics and possible 
disruption of COPII functions283. 
Unfolded protein response 
 The overexpression of transmembrane and soluble secreted proteins places 
increased biosynthetic load on the ER that can induce the UPR.  The UPR copes with 
increased biosynthetic load by producing additional protein folding chaperones, 
increasing the degradation of misfolded proteins, and decreasing the rate of protein 
translation284.  These three mechanisms all act in the short-term to decrease secretory 
throughput.  Over longer periods of time (days to weeks), these and other slow 
responses to ER stress lead to cell adaption and increased tolerance to secretory 
load285.  In the context of this secretory assay, UPR induction would dramatically 
decrease HRP synthesis and the rate of HRP’s secretory processing. 
 The overexpression of any transmembrane protein can induce the UPR, but the 
LPAT enzymes used in this screen are multi-span and have non-native GFP fusions; 
this makes misfolding not unlikely.  The UPR can also be induced by perturbation of 
membrane lipid composition due to LPAT activity286.  It has been reported that LPCAT3 
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knockdown, in combination with other stressors, leads to lipid imbalance and UPR 
induction287. 
 To determine if the UPR plays a role in LPAT mediated inhibition of secretion, it 
would be necessary to characterize the UPR state of LPAT overexpressing cells.  If the 
UPR is activated by LPAT overexpression, future experiments should investigate 
lowering LPAT expression levels, expressing untagged LPAT enzymes that may have a 
lower tendency to misfold, treatment with UPR antagonists, and the selection of a cell 
line with more robust secretory activity. 
 In selecting a LPAT from this screen for further study, I considered several 
criteria.  First, as a member of the AGPAT family had been extensively characterized by 
John Schmidt, a selection from the unstudied MBOAT family of enzymes was preferred.  
This left MBOAT1, MBOAT7, and LPCAT3 as potential candidates with strong inhibition 
of HRP secretion.  MBOAT7 is a LPI specific acyl transferase and as the biology of PI 
and PIPs has been extensively studied in other contexts, MBOAT1 or LPCAT3 was 
preferred.  The mechanism by which MBOAT proteins are localized to the ER was 
unknown.  LPCAT3 possesses an unconfirmed but canonical ER retention motif in its C-
terminus, while MBOAT1 does not.  LPCAT3 is also reported to be involved in the 
fascinating Lands cycle process of maintaining the asymmetry of saturated and 
unsaturated acyl chains between the sn-1 and sn-2 positions of phospholipids261.  
Therefore, LPCAT3 was selected for further study.  The characterization of LPCAT3’s 
predicted ER retention motif and transmembrane topological orientation will be the topic 
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of Chapter 4.  The role of LPCAT3 in regulating membrane trafficking will be the topic of 
Chapter 5. 
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CHAPTER FOUR:  LPCAT3 transmembrane topology 
Introduction 
 Human LPCAT3 is a multi-span transmembrane protein of 487 amino acids.  
LPCAT3 has a conserved MBOAT domain (pfam03062 in the NCBI’s Conserved 
Domain Database)288.  An accurate model for the topological orientation of MBOAT 
enzymes is important for understanding their function, particularly in regards to the 
availability of substrates at the active site and the location of enzymatic products.  The 
transmembrane topologies of human MBOAT family members SOAT1, SOAT2, and 
DGAT1 have been extensively investigated, likely due to the importance of these 
enzymes in cardiovascular disease 289–293.  However, these enzymes are not LPATs 
and are evolutionarily divergent from the human MBOAT LPATs (MBOAT1, MBOAT2, 
MBOAT7, and LPCAT3). 
 The only LPAT with an MBOAT domain that has had its transmembrane topology 
experimentally determined is the yeast protein Ale1294.  Pagac et al. examined the Ale1 
active site topology by constructing Ale1-SUC2-HIS4C chimeras.  Chimeras were 
constructed by C-terminal truncation and fusion to a dual topology reporter, SUC2-
HIS4C.  These studies determined that the active site histidine residue is oriented 
toward the lumen (Figure 4-1). 
LPCAT3 has a C-terminal amino acid sequence, KKME, that matches the 
K(x)KXX dilysine motif, an ER localization signal261,295.  This C-terminal amino acid 
conservation within the human MBOAT gene family is highlighted in Figure 4-2.  In 
some cases, substitution of positively charged (arginine or histidine) residues 
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Figure 4-1.  Topology of the yeast MBOAT Ale1 
A)  Transmembrane domain probability as predicted by TMHMM, B) transmembrane 
domains predicted by TOPCONS global alignment algorithm, and C) active site 
topology as inferred by EndoH band shift and histidine auxotrophy of yeast expressing 
four Ale1-SUC2-HIS4C variants.  Arrows indicate sites of C-terminal truncation and 
SUC2-HIS4C fusion.  Adapted from Pagac et al294.  
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LPCAT3 Leu Lys Lys Met Glu 
MBOAT1 Lys Arg Lys Tyr Asp 
MBOAT2 His Ser Ser Leu Lys 
MBOAT4 Lys His Lys Cys Asn 
MBOAT7 Lys Leu Arg Glu Glu 
Figure 4-2.  C-terminal sequence of MBOAT family LPATs 
LPCAT3, MBOAT1, and MBOAT4 have two lysines in their C-terminus conforming to 
the K(x)KXX ER localization motif.  The C-terminus of MBOAT7 contains a lysine and a 
positively charged arginine. 
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Figure 4-3.  MBOAT motifs essential for activity 
The residues of LPCAT3 that are essential for enzymatic activity, as shown by alanine 
replacement mutagenesis, Chinese hamster ovary cell overexpression, microsomal 
purification and in vitro lipase assay.  Adapted from Shindou et al298.  
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for lysine is a conservative mutation that maintains the ER localization activity of 
K(x)KXX motifs296,297. 
 Mutagenesis studies of LPCAT3 by Shindou et al have identified several 
residues (motifs) that are important for LPCAT3 enzymatic activity298.  Histidine 374 is 
very likely the catalytic amino acid as it is the best conserved amino acid of the MBOAT 
domain and its mutation abolishes catalytic activity in LPCAT3 and other MBOAT 
LPATs281,290,298–303.  Other important LPCAT3 motifs have been identified by Shindou et 
al. and are diagramed in Figure 4-3.  Depending on their topology, the motifs at amino 
acids 313, 434, and 451 could mediate LPCAT3 interaction with cytosolic acyl-CoA and 
alignment into the active site. 
Materials and methods 
Plasmids 
cDNA for LPCAT3 was obtained from OpenBiosystems (BC065194).  N-terminal HA, 
internal HA, and C-terminal myc tags were added to LPCAT3 by PCR extension and the 
coding sequence inserted into a pEGFP-N1 (Clontech) vector from which the EGFP 
coding sequence had been excised.  PCR extension of all LPCAT3 variants with 
internal HA epitopes used GGTAGGTACCGACCATGGCGTCCTCAGCGG as the 
forward primer and GGAAAGAGAAGTTAAAGAAGATGGAATAAGGATCCAAAG as the 
reverse primer.  Additional primers for the construction of HA epitope tagged LPCAT3 
are detailed in Table 4-1.  HA-LPCAT3(AAME) was constructed with the following 
reverse primer: 
TGGTGCCAAGGAAAGAGAAGTTAGCAGCAATGGAATAAGGATCCGGCG. 
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Table 4-1.  Oligonucleotide primer sequences 
HA 
epitope 
site 
Priming 
Direction 
Primer sequence (sense) 
N-
terminus 
Forward 
CCGTATGATGTGCCAGATTATGCGATGGCGTCCTCAGCGG 
AACTCGAGAACCATGTATCCGTATGATGTGCCAGATTATG 
GAAACTCGAGAACCATGTATCCG 
Reverse GGAAAGAGAAGTTAAAGAAGATGGAATAAGGATCCAAAG 
135 
Forward CCTTATGATGTGCCAGATTATGCAAACTACGATATCAAGTGGACAATG 
Reverse TATTACACTGCCACCGGCTATCCTTATGATGTGCCAGATTATGCA 
167 
Forward TATCCTTATGATGTGCCAGATTATGCATCCTTGTCCTCTGAGCAACA 
Reverse TGACGGAGGGAAAGATCAGAATTATCCTTATGATGTGCCAGATTATGCA 
218 
Forward 
GTGCCAGATTATGCAATACCAGGAAAGATACCAAACAGC 
TATCCTTATGATGTGCCAGATTATGCAATACCAGG 
Reverse GCAGGGAGAGCTGATTGACTATCCTTATGATGTGCCAGATTATGCA 
260 
Forward TATCCTTATGATGTGCCAGATTATGCATATGACAACCACCCCTTCTGG 
Reverse 
AGAAGACTATCTCCTCACTGAAGACTATCCTTATGAT 
CTCCTCACTGAAGACTATCCTTATGATGTGCCAGATTATGCA 
303 
Forward TATCCTTATGATGTGCCAGATTATGCAGGCTTTGAAGAAAAGGGCAAG 
Reverse GGGCCTGGGCTTCAATTATCCTTATGATGTGCCAGATTATGCA 
358 
Forward CATATCCGTATGATGTGCCACTGCTCAGCCCCCACA 
Reverse TCTACCTAGTGGGCTACACATATCCGTATGATGTGCCACT 
375 
Forward TATCCGTATGATGTGCCAGATTATGCGGGCCTGCACTCAGGAT 
Reverse CCTGGCCCTCTGGCACTATCCGTATGATGTGCCAGATTATGCG 
402 
Forward TATCCTTATGATGTGCCAGATTATGCAGAGAGCCCCACCCTGA 
Reverse GCTGCCAGGCTCATTCAATATCCTTATGATGTGCCAGATTATGCA 
445 
Forward 
CCAGATTATGCAAAATGGCTTAAGGTGTATAAATCCATCT 
TATCCTTATGATGTGCCAGATTATGCAAAATGGCTTAAGG 
Reverse GCCTCTTCACGTGGGACTATCCTTATGATGTGCCAGATTATGCA 
 
80 
 
LPCAT3-myc was constructed with the following reverse primers: 
TCGCTGATGAGTTTTTGTTCTTCCATCTTCTTTAACTTCTCTTTCCTTG and 
CAAAGCGGCCGCTTATAAATCTTCTTCGCTGATGAGTTTTTGTTCTTCC. 
Cell culture 
HeLa cells were grown and maintained in MEM supplemented with 10% FBS and 1% 
penicillin/streptomycin at 37°C in 95% humidity and 5% CO2 environment.  Cells were 
transfected in 35 mm2 culture dishes using PEI from Polysciences Inc. according to the 
manufacturer’s instructions.  DNA transfection was performed using 1 μg DNA/5 μg PEI 
for the 24 h prior to experiments. 
IF microscopy 
  Cells were grown on glass coverslips and fixed with 3.7% formaldehyde in PBS, 
washed 3 times in PBS, and permeabilized with 0.1% Triton X-100 in PBS or digitonin 
solution (3 μg/ml digitonin, 0.3 M sucrose, 5 mM MgCl2, 120 mM KCl, 0.14 mM CaCl2, 2 
mM EGTA, 25 mM HEPES pH to 7.6 with KOH).  Cells were incubated with primary 
antibodies for 1 h at room temperature using the manufacturer’s recommended dilution, 
washed 3 times, treated identically with secondary antibodies, and mounted on glass 
slides with VectaShield (Vector Laboratories).  Cells were viewed and imaged using a 
Perkin-Elmer Ultraview spinning disk confocal microscope at 100X.  Image analysis was 
performed using the ImageJ software package (NIH, Bethesda, MD) or the FIJI 
distribution of ImageJ254.  To calculate Pearson’s correlation coefficient for K(x)KXX 
colocalization experiments, a threshold was applied to the GPP130 channel, the mask 
smoothed, enlarged by 2 pixels, and converted to a selection.  Selection was applied as 
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a region of interest (ROI) for Pearson’s correlation calculation using the “Colocalization 
Threshold” tool.  Error bars are SEM.  Significance determined by paired Student’s t-
test. 
Computational methods 
The TMHMM Server v. 2.0 (http://www.cbs.dtu.dk/services/TMHMM/) and TOPCONS 
server (http://topcons.cbr.su.se/) with the default settings were used to predict LPCAT3 
membrane topology304,305.  The second prediction provided by the TOPCONS server 
(Figure 4-8) was performed with the following restrainment parameters: “1-1-o;487-487-
i;135-135-o;167-167-i;218-218-i;260-260-o;303-303-i;402-402-i;445-445-o;”.  Amino 
acid conservation, protein sequence alignment, and phylogenetic relationships were 
determined using the Conserved Domain Database, Clustal Omega, and the PHYLIP 
package257,258,288.  Glycosylation prediction performed by the NetNGlyc 
(http://www.cbs.dtu.dk/services/NetNGlyc/) and NetOGlyc 
(http://www.cbs.dtu.dk/services/netoglyc/) servers306,307. 
Results 
Computational prediction of LPCAT3 transmembrane domain orientation and 
glycosylation 
 TMHMM is a transmembrane prediction algorithm that models helix length, 
hydrophobicity, charge bias, and the alternation of cytoplasmic and luminal loops.  It has 
been shown to correctly predict the transmembrane topology of approximately 77% of 
membrane proteins and has been applied to the identification of membrane proteins in a 
large collection of genomes304.  It predicted that LPCAT3 has seven transmembrane 
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Figure 4-4.  TMHMM predicted transmembrane domains of LPCAT3 
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Figure 4-5.  TOPCONS predicted transmembrane domains of LPCAT3 
Blue: lumen, red: cytoplasm. 
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domains, a luminal N-terminus, a cytoplasmic C-terminus, and a luminal active site 
(Figure 4-4).   
 The TOPCONS topology prediction server combines the predictions of five 
topology prediction algorithms into a consensus prediction and quantifies the reliability 
of the prediction based on the degree of consensus.  The prediction can also be 
restrained by experimentally determined cytoplasmic and luminal loops.  A naïve 
prediction by the TOPCONS server showed 10 transmembrane domains, a luminal N-
terminus, luminal active site and cytoplasmic C-terminus (Figure 4-5). 
 O-linked glycosylation takes place at serine and threonine sites in regions that 
are enriched in serine, threonine, proline, and alanine308.  N-terminal glycosylation is 
known to be important for the proper function and membrane trafficking of some 
transmembrane proteins.  For instance, a mutation within the human potassium ion 
channel subunit KCNE1 that eliminates N-terminal glycosylation has been identified as 
causing long QT syndrome, a form of congenital heart disease309.  Glycosylation can 
only happen within the lumen of the ER and would stabilize the topological orientation of 
the glycosylation site within the ER.  The NetNGlyc and NetOGlyc glycosylation site 
prediction servers identified serine 3 and serine 4 as potential LPCAT3 N-linked 
glycosylation sites (no O-linked glycosylation sites were predicted)306,307.  Mammalian 
LPCAT3 homologues have a conserved serine/threonine residue in an alanine rich 
region of the N-terminus (Figure 4-6).  If these sites are glycosylated in the lumen of the 
ER, it would stabilize the topological orientation of their N-termini.   
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H. sapiens Met Ala Ser Ser Ala Glu 
M. musculus Met Ala Ser Thr Ala Asp 
B. taurus Met Ala Ser Ala Ala Glu 
C. lupus Met Ala Ser Ala Ala Glu 
Figure 4-6.  N-terminal sequences of mammalian LPCAT3 homologues show 
conservation of potential O-linked glycosylation site   
LPCAT3 from humans, mouse, cow, and dog have a conserved serine/threonine within 
an alanine rich region.  This motif is predicted to be an O-linked glycosylation site. 
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Selective permeabilization reveals topological orientation of LPCAT3 
 The topology model of Ale1 reported by Pagac et al. predicts a catalytic histidine 
in the lumen of the ER but provides no information concerning the topology of most 
extra-membrane loops294.  To more completely map LPCAT3 transmembrane domain 
topology, HA epitope tags were inserted by mutagenesis into 10 predicted loop regions.   
The selection of epitope tag insertion sites was guided by a previously published 
predicted topology, the Ale1 topology studies of Pagac et al., the computer generated 
topology predictions shown above, and amino acid conservation estimates294,310.  
Epitopes were inserted into predicted extra membrane loops with preference to regions 
of low amino acid conservation. 
 The topological orientation of each epitope was probed by IF in combination with 
selective membrane permeabilization, as described by Hailey et al.311.  Cells transfected 
with epitope tagged LPCAT3 were permeabilized by treatment with either Triton X-100 
or digitonin.  Triton X-100 permeabilizes all cellular membranes and will expose every 
epitope for antibody binding.  Digitonin, at the concentration used, permeabilizes only 
the plasma membrane while leaving intracellular membranes intact.  Thus, only 
epitopes exposed on the cytoplasmic side of intracellular membranes, but not luminal 
ones, will be available for antibody binding.  In addition to antibodies targeting the HA 
epitope, cells were probed with a rabbit polyclonal that had been raised against a 
synthetic peptide corresponding to the C-terminus of LPCAT3. 
 HA epitopes inserted after amino acids 167, 218, 303, 375, and 402 showed 
reticular ER staining using both Triton and digitonin permeabilization, indicating that 
they face the cytoplasm (Figure 4-7).  HA epitopes inserted at the N-terminus and after 
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Figure 4-7.  Selective permeabilization reveals the topological orientation of 
LPCAT3 
The two leftmost columns show LPCAT3 IF using Triton-100 permeabilization.  The two 
rightmost columns were cells permeabilized using digitonin.  Cells were simultaneously 
probed by antibodies against both the HA epitope and the C-terminus of LPCAT3. 
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amino acids 135, 260, and 445 showed reticular ER staining using Triton 
permeabilization but not using digitonin permeabilization, indicating that these epitopes 
face the lumen.  An HA epitope inserted after amino acid 358 could not be detected 
using either Triton or digitonin, indicating a sterically shielded local environment with 
inconclusive topology. 
Refined model of LPCAT3 topology 
 A second round of topology prediction through the TOPCONS server was 
performed using the selective permeabilization results as restraints.  With these 
restraints in place, the minimum reliability of prediction increased from less than 40% to 
greater than 75% (Figure 4-8).  Based on this prediction, I proposed a topology model 
that included 11 transmembrane domains and a luminal active site (Figure 4-9). 
Exclusion from the Golgi requires C-terminal dilysine motif 
 The localization of LPCAT3 to the ER is suspected to be dependent on an ER-
retrieval motif, K(x)KXX, at the extreme C-terminus310.  The K(x)KXX motif is a binding 
site for COPI coatomer and facilitates sorting into budding COPI vesicles296.  Human 
MBOAT1, MBOAT4, and MBOAT7 contain similar C-terminal motifs that might function 
as ER retrieval signals, although MBOAT2 lacks this motif (Figure 4-2).  To explore the 
importance of the K(x)KXX motif for LPCAT3 localization, the localization of three 
overexpression constructs was compared.  These constructs were 1) a positive control 
with a wild-type sequence and an N-terminal HA epitope tag (HA-LPCAT3 KKME), 
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Figure 4-8. Restrained TOPCONS predicted transmembrane domains of LPCAT3 
The TOPCONS algorithm was restrained as follows.  Amino-terminus: lumen, amino 
acid (aa) 135: lumen, aa 167: cytoplasm, aa 218: cytoplasm, aa 260: lumen, aa 303: 
cytoplasm, aa 402: cytoplasm, aa 445: lumen, and carboxyl-terminus: cytoplasm.  
Green arrows indicate the approximate locations of HA epitope insertion sites.  Blue: 
lumen, red: cytoplasm. 
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Figure 4-9.  LPCAT3 transmembrane topology model 
Human LPCAT3 has a luminal active site and eleven transmembrane domains.  Green 
dashes indicate the location of HA epitope tags.  The catalytic histidine is labeled in red. 
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Figure 4-10.  Exclusion from the Golgi requires a C-terminal K(x)KXX motif 
A) IF of overexpressed LPCAT3 and endogenous GPP130 shows exclusion from the 
Golgi complex of wild-type N-terminally epitope tagged LPCAT3 (HA-LPCAT3 KKME), 
partial Golgi localization of mutated LPCAT3 (HA-LPCAT3 AAME), and strong Golgi 
localization of C-terminally epitope tagged LPCAT3 (LPCAT3-MYC).  B)  Quantitation of 
colocalization between LPCAT3 and GPP130 by Pearson’s correlation coefficient.  
(n=5) 
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2) an alanine substituted mutant (HA-LPCAT3 AAME) with an N-terminal HA epitope 
tag, 3) and a wild-type sequence with a C-terminal myc epitope fusion (LPCAT3-MYC).  
The localization of these three constructs was examined in HeLa cells and compared to 
the localization of the cis-Golgi glycoprotein GPP130 (Figure 4-10).  To quantitate 
differences in colocalization with GPP130, the Pearson’s correlation coefficient was 
calculated between the fluorescent intensity of GPP130 and LPCAT3.  Relative to the 
N-terminally tagged positive control, both C-terminally modified proteins increasingly 
localized to the Golgi complex. 
Discussion 
LPCAT3 active site topology 
 Reports of MBOAT transmembrane topologies have been contradictory, though 
most evidence points to MBOAT proteins having a luminal active site291,293.  What is 
clear is that the enzyme MBOAT4 must have a luminal active site, because it acylates 
secreted proteins202.  Also, Pagac et al. convincingly identify a luminal active site in 
yeast Ale1202,294.  The evidence I have presented here also supports a model of a lumen 
facing active site for LPCAT3.  Specifically, I showed that an HA epitope inserted after 
amino acid 375, adjacent to the active site histidine 374, has luminal localization.  Also, 
the immediately adjacent loop regions were shown to be cytosolic by the mapping of HA 
epitopes at amino acids 303 and 402. 
 The topological location of an HA epitope inserted after amino acid 358 could not 
be determined.  IF using either Triton or digitonin permeabilization did not detect the 
epitope.  Lack of staining is likely due to a protein folding state that does not allow the 
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anti-HA antibody to bind the epitope and not due to a lack of protein expression or 
protein degradation.  The protein appears to have been synthesized completely, as the 
C-terminus could be detected in the cytosol by immunofluorescence (Figure 4-7) and 
the HA epitope could be detected by Western blot (data not shown). 
 The topology model presented here places the active site histidine 374 at the 
border of a transmembrane domain and a very short luminal loop.  However, it is 
impossible to conclusively discriminate between the localization of the active site to a 
luminal extra-membrane loop or to the luminal edge of a transmembrane domain.  
Either location necessitates that cytosolic acyl-CoA traverse the membrane to a luminal 
active site.  Consequentially, conserved cytosolic motifs must recognize acyl-CoA and 
mediate membrane traversal.  Intriguingly, the two largest extra-membrane loops (158-
229 and 287-356) are localized to the cytoplasm and contain highly conserved residues 
(Figure 4-3, Figure 4-9).  Shindou et al. reported several amino acids that are required 
for LPCAT3 activity, including tryptophan 313 and aspartic acid 314298.  Additionally, 
asparagine 318 and asparagine 338 in the 287-356 loop and glycine 200 and proline 
201 in the 158-229 loop have perfect conservation across human MBOAT LPATs and 
yeast Ale1. 
Topological map 
 When interpreting the topological map in Figure 4-9, it is important to keep in 
mind the shortcomings of the techniques from which it was constructed.  First, it should 
be understood that the topology of three extra-membrane loops (starting at amino acids 
63, 89, and 111) has not been experimentally verified.  Also, the insertion of an epitope 
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tag may disrupt the native structure, charge distribution, and potentially the membrane 
topology of LPCAT3.  It is somewhat reassuring that for every epitope tag, the C-
terminus of LPCAT3 localized to the cytoplasm. 
 Membrane re-entrant structures are regions that are hydrophobic enough to dip 
into the membrane, but do not fully penetrate to the other side312.  It is possible that the 
insertion of an HA-epitope into a long, membrane re-entrant structure would create two 
new transmembrane helixes flanked by a new extra-membrane loop, which contains the 
epitope.  Such a topology change would have no effect on the localization of the C-
terminus312.  This consideration applies most particularly to the interpretation of the two 
short loop regions spanning amino acids 133-136 and 378-379. 
 The topology prediction for the first four transmembrane helixes of LPCAT3 (42-
132) has lower reliability than that of any other region.  This is in part because the 
modeling of these transmembrane domains is constrained only by the N-terminus and 
an HA-epitope at amino acid 135 (Figure 4-8).  Additionally, this region appears to be 
difficult to predict computationally.  There is no agreement in this region between the 
predictions of the TMHMM server, the naïve TOPCONS algorithm and the restrained 
TOPCONS algorithm. 
 An O-linked glycosylation site is predicted in the luminal N-terminus of 
LPCAT3308.  This glycosylation motif is conserved across mammalian LPCAT3 
homologues (Figure 4-6).  Cotranslational translocation during the biosynthesis of 
transmembrane proteins often takes place in conjunction with posttranslational 
modification by glycosyltransferases87.  Topology prediction algorithms have the lowest 
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reliability score in the first four predicted transmembrane domains of LPCAT3, possibly 
indicating that this region exists on the borderline of stability.  The placement of a 
cotranslational glycosylation site at the N-terminus of LPCAT3 could enable more 
efficient protein folding by stabilizing the topological orientation of the N-terminus to the 
lumen, constraining the topological orientation of subsequent transmembrane domains. 
ER localization motif 
 The cytosolic C-terminal K(x)KXX ER localization motif of LPCAT3 was shown to 
be important for maintaining LPCAT3 localization to the ER and exclusion from the 
Golgi complex (Figure 4-10).  This motif interacts with COPI coatomer and is 
responsible for recruitment to retrograde transport vesicles295.  Mutation of the dilysine 
residues to alanine residues was effective at relocalizing LPCAT3 to the Golgi complex 
but not as effective as the fusion of an epitope tag to LPCAT3’s C-terminus.  It is likely 
that other motifs in LPCAT3’s C-terminus contribute to ER localization.  There are 
several other basic amino acid dependent mechanisms for ER localization such as 
those mediated by the KDEL receptor’s C-terminal KKLSLPA sequence and the RXR 
and FLxK motifs54,295,313.   
 Sequences similar to the K(x)KXX motif can be found in MBOAT1, MBOAT4, and 
MBOAT7.  These sequences have not been investigated experimentally but likely play a 
role in the ER localization pattern of these proteins.  Interestingly, MBOAT2 may 
localize to the ER by a different mechanism, as it does not have a C-terminal sequence 
similar to the K(x)KXX motif. 
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 In summary, my studies have defined the membrane topology of human LPCAT3 
by mapping the N- and C-termini, 11 transmembrane domains, and the likely luminal 
catalytic histidine residue.  In addition, I have identified C-terminal motifs, including a 
K(x)KXX motif, that are likely required for Golgi to ER retrieval. 
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CHAPTER FIVE:  LPCAT3 regulates retrograde trafficking from the 
Golgi complex 
Introduction 
 Previous reports showed that overexpressed LPCAT3 was localized to the ER 
and to karmellae-like structures, which I confirmed in the studies presented in Chapter 3 
and 4261.  It prefers long-chain, unsaturated acyl-CoA donors and LPC acceptors310,314.  
Expression is ubiquitous, high in metabolically active cells, and greatest in the liver, 
adipose tissue, and pancreas261.  The siRNA mediated knockdown of LPCAT3 in 
human hepatoma Huh7 cells nearly eliminated membrane bound LPC acyltransferase 
activity310.  Adenoviral knockdown in mice attenuated hepatic LPC acyltransferase 
activity, increased hepatic LPC concentration, and increased hepatic triglyceride 
secretion140.   
 Little is known about how LPCAT3 regulates membrane trafficking.  In Chapter 3, 
I established that LPCAT3 overexpression inhibits ssHRP secretion.  In this chapter, I 
characterize the effect of LPCAT3 overexpression and knockdown on  
organelle morphology and membrane trafficking. 
Materials and methods 
Cell Culture 
HeLa cells were grown and maintained in MEM supplemented with 10% FBS and 1% 
penicillin/streptomycin at 37°C in a 95% humidity and 5% CO2 environment.  Cells were 
transfected in 35 mm2 culture dishes using PEI from Polysciences Inc. according to the 
manufacturer’s instructions.  DNA transfection was performed using 1 μg DNA/5 μg PEI 
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for the 24 h prior to experiments.  Knockdown was performed using Lipofectamine 
RNAiMAX (Life Technologies) twice prior to experiments, at 24 h and 48 h, using 25 
pmoles of siRNA/3 μl RNAiMAX according to the manufacturer’s instructions.  Two 
siRNAs targeting the LPCAT3 coding sequence (Ambion siRNA 122586: 
CCAUUGCCUCAUUCAACAUtt and 16819: GGGAAAGAUCAGAAUUCCUtt) were 
tested for LPCAT3 knockdown; 16819 was most effective and subsequently used for all 
experiments (Figure 5-6).  Ambion AM4611 siRNA was used as negative control. 
IF microscopy 
Rabbit anti-GPP130 (Covance), mouse anti-HA (Covance), rabbit anti-HA (Santa Cruz), 
mouse anti-myc (Cell Signaling), rabbit anti-LPCAT3 C-terminus (NEOBioscience, 
Cambridge, MA), and FITC/TRITC conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratories and Invitrogen) were used for IF.  Cells were grown on 
glass coverslips and fixed with 3.7% formaldehyde in PBS, washed 3 times in PBS, and 
permeabilized with 0.1% Triton X-100 in PBS.  Cells were incubated with primary 
antibodies for 1 h at room temperature using the manufacturer’s recommended dilution, 
washed 3 times, treated identically with secondary antibodies, and mounted on glass 
slides with VectaShield (Vector Laboratories).  Cells were viewed and imaged using a 
Perkin-Elmer Ultraview spinning disk confocal microscope at 100X.  Image analysis was 
performed using the ImageJ software package (NIH, Bethesda, MD) or the FIJI 
distribution of ImageJ254.  Error bars are SEM.  Significance determined by paired 
Student’s t-test. 
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ssHRP secretion assay 
To perform the HRP secretion assay, cells were washed 3 times in MEM without FBS 
and then incubated in MEM containing 3% FBS.  After 6 h, 10 μl duplicate samples 
were removed to a 96-well plate and 50 μl of TMB chromogenic reagent (Pierce) was 
added to each.  The reaction was allowed to proceed until saturation, halted by the 
addition of 50 μl 1 M sulfuric acid, and absorbance measured at 450 nm. 
Brefeldin A induced Golgi recycling assay 
To examine membrane tubule-mediated retrograde trafficking form the Golgi to the ER, 
I took advantage of Brefeldin A (BFA) (Endo Life Sciences or Sigma-Aldrich).  Cells 
were washed 3 times with 37°C MEM without FBS followed by incubation with 1 μg/ml 
BFA at 37°C.  Coverslips were fixed at 0 min, 8 min, and 20 min timepoints and 
prepared for IF of endogenous GPP130.  Scoring for intact Golgi complexes was 
performed by visual inspection with wide field epifluorescence at 100X magnification.  At 
the 8 min time point, cells were categorized as having ‘ER localization’ if GPP130 was 
partially localized to reticular ER.  At the 20 min time point, cells were categorized as 
having ‘completed recycling’ if GPP130 localized to the reticular ER and an intact Golgi 
could not be found.  Membrane tubules were counted in cells at the 8 min time point. 
ERGIC-53 recycling assay 
 For ERGIC-53 transport assays, I used the temperature shift protocol to induce 
tubule-mediated retrograde transport from the ERGIC to the ER315.  Cells were washed 
with bicarbonate buffered MEM containing 10% FBS, held at 15°C for 4 h, washed with 
37°C MEM containing 10% FBS, and shifted to 37°C.  Coverslips were fixed at 0 min, 2 
min, and 5 min post-temperature shift and prepared for IF of HA-LPCAT3.  Scoring for 
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ER localized ERGIC-53-GFP was performed by visual inspection under a mercury lamp 
at 100X. 
VSV-G transport assay 
 For YFP-VSV-G-ts045 transport assays, cells were held at 40°C for 18 h and 
then shifted to 32°C.  Cells from the 8 min time point were scored based on the 
presence of Golgi staining; cells at 40 min were scored based on the presence of 
plasma membrane staining. 
Results 
Localization of overexpressed LPCAT3 and organelle morphology 
 Overexpressed LPCAT3 localized to the ER and induced the formation of 
karmellae-like membrane structures (Figure 5-1).  The physiological significance of 
karmellae is unclear, but they are not inherently detrimental to cell health and not 
uncommon when transmembrane proteins are overexpressed260.  Indeed, all of the 
AGPAT and MBOAT family members shown in Figure 3-1 had a propensity to localize 
to large puncta/karmellae-like structures.  When overexpressed in HeLa cells, GFP-
LPCAT3 and HA-LPCAT3 could be found throughout the ER, nuclear envelope and in 
karmellae-like structures (Figure 5-1, Figure 5-2). 
 Overexpression of LPCAT3 altered the localization of some markers of the early 
secretory system (Figure 5-2).  GFP-ERGIC-53 became less juxta-Golgi in localization 
and increasingly localized to juxtanuclear puncta and to the reticular ER.  An ER 
resident (v)R-SNARE protein, Sec22, colocalized nearly perfectly with 
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Figure 5-1.  LPCAT3 localization 
When overexpressed in HeLa cells, N-terminally GFP tagged human LPCAT3 localized 
to the ER, to the nuclear envelope, and to large puncta/karmellae-like structures. 
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LPCAT3, although its distribution was largely unchanged by LPCAT3 overexpression.  
The COPII components Sec24 and Sec31 showed a decrease in the number of 
disperse puncta and Sec24 showed an increase in juxta-Golgi localization.  The COPI 
component β-COP showed a dramatic loss of peripheral puncta and greatly increased 
juxta-Golgi localization. 
 Despite the LPCAT3 overexpression induced change in the localization of 
markers of the early secretory system, LPCAT3 overexpression did not appear to 
grossly affect the morphology of the Golgi complex, TGN, AP-1 labeled vesicles, or 
EEA1 labeled endosomes (data not shown). 
HA-LPCAT3 overexpression inhibits HRP secretion 
 In order to confirm the findings of the HRP secretion screen from Chapter 3, 
which identified GFP-LPCAT3 as an inhibitor of HRP secretion, the HRP secretion 
experiment was repeated with HA epitope tagged LPCAT3.  In agreement with the HRP 
screen (Figure 3-4), secretion was dramatically reduced in cells co-overexpressing HA-
LPCAT3 (Figure 5-3).  HRP colocalized with LPCAT3 to karmellae-like structures, but 
also localized to the ER and Golgi complex. 
HA-LPCAT3 overexpression had no effect on ERGIC-53 retrograde trafficking 
kinetics 
 Once a defect in HRP secretion was confirmed for cells overexpressing HA-
LPCAT3, the kinetics of other membrane trafficking processes were measured.  ERGIC-
53 traffics between the ER, ERGIC, and cis-Golgi but can be held in the ERGIC by a 
15°C temperature block43.  Removal of this temperature block induces a bolus of 
ERGIC-53 trafficking to the ER by vesicular and tubular membrane trafficking 
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Figure 5-2.  LPCAT3 overexpression disrupts the localization of early secretory 
system markers 
The overexpression of LPCAT3 affected the localization of ERGIC-53-GFP and 
endogenous Sec24, Sec31, and β-COP.  LPCAT3 had near perfect colocalization with 
Sec22-myc. 
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Figure 5-3.  HA-LPCAT3 overexpression decreased HRP secretion 
A)  Colocalization of ssHRP and LPCAT3 to karmellae–like structures of the ER.  B)  
ssHRP secretion measurements.  (n=4, * p<0.01)   
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intermediates39.  Despite the altered ERGIC morphology (Figure 5-2), the 
overexpression of HA-LPCAT3 had no obvious effect on the kinetics of retrograde 
ERGIC-53 trafficking by this assay (Figure 5-4). 
HA-LPCAT3 overexpression had no effect on VSV-G secretion 
 There are at least three COPII mediated routes of anterograde trafficking from 
the ER316.  HRP is a soluble luminal protein that is expected to be secreted by ‘bulk’ 
trafficking, whereas the integral membrane protein VSV-G has a cytoplasmic motif that 
coordinates its enrichment in COPII vesicles28.  The temperature sensitive VSV-G 
mutant ts045 does not fold properly at the non-permissive temperature of 40°C and is 
retained in the ER by protein quality control machinery86.  The involvement of LPCAT3 
in VSV-G transport was assayed by shifting cells from 40°C to 32°C and measuring the 
trafficking kinetics of YFP-VSV-G-ts045 anterograde transport.  No change in VSV-G 
transport kinetics, to the Golgi complex was observed (Figure 5-5). 
siRNA treatment to knockdown overexpressed LPCAT3 
 LPCAT3 is broadly expressed in mammalian cells and its knockdown in HeLa 
cells decreases polyunsaturated fatty acid incorporation into PC, PS, and PE317.  An 
antibody raised to the C-terminus of LPCAT3 is capable of detecting overexpressed 
LPCAT3 in HeLa cells; overexpressed LPCAT3 could be detected by both Western blot 
and IF.  However, endogenous LPCAT3 could not be detected in HeLa cells, HepG2 
cells, or BTRD cells (Figure 5-6, data not shown). 
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Figure 5-4.  LPCAT3 overexpression did not affect the kinetics of ERGIC-53 
recycling 
A) HeLa cells co-overexpressing GFP-ERGIC-53 and HA-LPCAT3 were held at 15°C 
and then shifted to 37°C.  Recycling of ERGIC-53 to the ER was unaffected by co-
overexpressed HA-LPCAT3.  B) Quantitation of A.  (n=4) 
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Figure 5-5.  VSV-G transport was unaffected by HA-LPCAT3 co-overexpression 
A) YFP-VSV-G-ts045 was expressed in HeLa cells in combination with HA-LPCAT3.  
Cells were held at 40°C and then shifted to 32°C.  Transport of VSV-G to the Golgi and 
the plasma membrane was unaffected by co-overexpressed HA-LPCAT3.  B) 
Quantitation of the 8 min time point showing localization of VSV-G to the Golgi complex.  
(n=3) 
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 Ambion 16819 siRNA was demonstrated by Zhao et al. to knockdown LPCAT3 
human hepatic Huh7 cells.  I found it effective for the knockdown of overexpressed 
LPCAT3 and used it exclusively for the following experiments (Figure 5-6). 
LCPAT3 knockdown disrupts ERGIC, COPI, and COPII markers 
 Changes in the morphology or localization of organelle markers indicate 
disruption of membrane trafficking.  To detect organelle morphology changes caused by 
LPCAT3 knockdown, IF was performed for a variety of organelle markers.  In 
knockdown cells, ERGIC-53-GFP, endogenous Sec24, Sec31, and β-COP exhibited 
decreased localization to peripheral puncta and a variable increase in juxta-Golgi and 
juxta-nuclear localization (Figure 5-7).  β-COP localization was especially disrupted, 
with nearly complete depletion of peripheral puncta.  These results indicate that siRNA 
treatment affected the morphology and steady state distribution of the early secretory 
system. 
 However, it appears that the alteration of membrane trafficking in LPCAT3 
knockdown cells has limited scope.  Despite the disruptions of early secretory markers 
that are seen in LPCAT3 knockdown cells, the localization of the ER marker Sec22-myc 
and the endogenous cis-Golgi protein GPP130 was not altered (Figure 5-8).  
Additionally, the localization of TGN markers, AP-1, and EEA1 labeled endosomes was 
likewise unaffected (data not shown).  Given these findings, it is likely that only the early 
secretory system was disrupted in siRNA treated cells. 
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Figure 5-6.  Knockdown of LPCAT3 
A) Representative Western blot using a custom anti-LPCAT3 C-terminus polyclonal 
antibody to detect knockdown of overexpressed HA-LPCAT3.  B) Quantitation of tubulin 
normalized LPCAT3 overexpression relative to vector overexpressing, siControl treated 
cells.  n=3 
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Figure 5-7.  LPCAT3 Knockdown disrupts markers of the early secretory system 
Treatment with LPCAT3 siRNA disrupted GFP-ERGIC-53, Sec24, Sec31, and β-COP 
localization.  All disrupted markers showed decreased peripheral puncta and variably 
increased juxta-Golgi and juxta-nuclear localization. 
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Figure 5-8.  Knockdown of LPCAT3 does not affect the localization of GPP130 or 
Sec22 
Knockdown of LPCAT3 in HeLa cells does not disrupt the localization of endogenous 
GPP130 or transiently transfected Sec22-myc. 
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Figure 5-9.  Knockdown delays BFA induced Golgi recycling to the ER 
A)  Golgi morphology as shown by GPP130 staining in RNAi treated HeLa cells at 8 min 
and 20 min post-BFA treatment.  B)  Quantitation of A. (n=3, * p<0.01) 
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Figure 5-10.  LPCAT3 siRNA treatment enhances BFA stimulated Golgi tubulation 
siRNA treated HeLa cells were examined 8 min after treatment with BFA.  A) 
Representative images of GPP130 labeled tubules.  B)  Quantitation of tubulation.   
(n=4) 
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Knockdown slows BFA mediated Golgi recycling to the ER 
 In response to BFA, the Golgi apparatus undergoes massive tubulation and 
subsequent trafficking to, fusion with, and absorption by the ER.  It has been previously 
shown that BFA mediated recycling and membrane tubulation is influenced by other 
LPATs181,245,318.  In order to determine if LPCAT3 activity plays a role in this process, 
BFA stimulated recycling of GPP130 was measured at 8 min and 20 min timepoints in 
knockdown cells.  At each timepoint, Golgi recycling to the ER was slower in siLPCAT3 
cells than in siControl cells (Figure 5-9). 
LPCAT3 knockdown increased Golgi membrane tubulation in response to BFA 
treatment 
 The retrograde trafficking of the Golgi complex to the ER in response to BFA 
treatment is characterized by extensive Golgi membrane tubulation.  Quantitation of the 
extent of tubulation revealed, surprisingly, that siLPCAT3 treated cells had increased 
tubulation at the 8 min time point (Figure 5-10). 
LPCAT3 Knockdown inhibited ERGIC-53 retrograde trafficking 
 Treatment with siLPCAT3 was shown to disrupt the localization of ERGIC-53, 
inducing a more juxta-Golgi and juxta-nuclear localization (Figure 5-7).  This result 
indicated that LPCAT3 activity may be necessary for regulating ERGIC-53 retrograde 
trafficking.  To confirm this hypothesis, the kinetics of membrane tubule-mediated 
retrograde trafficking of ERGIC-53 in response to 15°C to 37°C temperature shift was 
measured.  Similar to the BFA results, siLPCAT3 treated cells exhibited slowed 
retrograde trafficking, but ERGIC-53 membrane tubulation actually increased. 
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Figure 5-11.  Knockdown of LPCAT3 inhibits retrograde trafficking and promotes 
tubulation of ERGIC-53 
Treatment of HeLa cells with LPCAT3 siRNA slows the trafficking of ERGIC-53-GFP to 
the ER following 15°C to 37°C temperature shift.  A)  Time points following temperature 
shift.  Note the long membrane tubules in knockdown cells at the 2 and 5 min time 
points.  B)  Quantitation of ERGIC trafficking. (n=7, * p < 0.01, *** p < 0.0001)  C)  
Quantitation of ERGIC tubulation. (n=3) 
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Figure 5-12.  Knockdown does not affect anterograde trafficking of VSV-G 
VSV-G-YFPts045 was held in the ER by 40°C temperature block and shifted to 30°C to 
initiate trafficking.  Trafficking to the Golgi at 8 min and the PM at 40 min was 
unaffected.  A) Representative images of VSV-G-YFPts045.  B)  Quantitation of Golgi 
localization at 8 min.  (n=3)  
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LPCAT3 knockdown did not affect transport of VSV-G through the secretory 
pathway 
 The secretory system requires a balanced flow of anterograde and retrograde 
trafficking between compartments to maintain organelle integrity.  Slowed retrograde 
trafficking from the Golgi to the ER may be accompanied by slowed anterograde 
trafficking of either VSV-G or ssHRP.  To determine if this was the case, the kinetics of 
secretion were measured.  Treatment of HeLa cells with LPCAT3 siRNA did not affect 
the kinetics of VSV-G transport from ER to Golgi complex (Figure 5-12).  Likewise, cells 
treated with LPCAT3 siRNA did not have any defects in HRP secretion (data not 
shown). 
Discussion 
The major findings in this chapter are that changing the levels of LPCAT3 expression 
can have a significant effect on intracellular membrane trafficking, although not always 
in a predictable way.  For example, overexpression and knockdown of LPCAT3 do not 
necessarily produce opposite effects on membrane trafficking.  Perhaps the most robust 
trafficking defect was the inhibition of retrograde trafficking from the Golgi complex to 
the ER, as observed by two independent measures.  Both of these retrograde pathways 
are mediated by the formation of membrane tubules.  Surprisingly, however, knockdown 
of LPCAT3, although inhibiting retrograde trafficking, actually resulted in the formation 
of increased numbers of membrane tubules.  At first glance, these results appear 
counter-intuitive; however, they can be explained by a simple model by which LPCAT3 
knockdown results in the prolonged persistence of membrane tubules and the 
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decreased retrograde trafficking.  I will expand below on the possible mechanistic 
explanations for these results. 
Disruption of lipid remodeling by LPCAT3 overexpression 
 LPCAT3 overexpression induces the formation of ER karmellae, inhibits HRP 
secretion, and disrupts the localization of ERGIC-53 and markers of COPII and COPI 
vesicles.  In Chapter 3, the mechanisms by which LPAT overexpression could inhibit 
HRP secretion were discussed.  Briefly, these mechanisms were the induction of the 
UPR, disruption of COPII trafficking, and disruption of lipid remodeling.  Further 
investigation is required to determine precisely how LPCAT3 overexpression affected 
membrane trafficking, however the most relevant mechanisms related to lipid 
remodeling are discussed below. 
 Phospholipids produced de novo by the Kennedy pathway have a high degree of 
saturation at the sn-1 and sn-2 position177.  LPCAT3 enzymatic activity increases 
unsaturation at the sn-2 position creating asymmetry between the sn-1 and sn-2 
position261.  In comparison to symmetric, fully saturated phospholipids, asymmetric 
phospholipids induce negative membrane curvature, increase membrane fluidity, prefer 
liquid-disordered (Ld) phase states, and induce phase separation
269.  Also, they are 
preferred by some lipid remodeling enzymes and membrane binding domains319. 
 While LPCAT3 activity produces asymmetric acyl chain saturation at the sn-1 
and sn-2 positions, LPCAT3 activity is not expected to create phospholipid asymmetry 
across the ER membrane bilayer.  In the ER, phospholipid flippases transport 
phospholipids across the membrane, equalizing their concentration on each side of the 
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bilayer320.  During the course of anterograde trafficking, however, the action of cytosolic 
lipases may establish a phospholipid gradient across the bilayer. 
 LPCAT3 activity has been shown to reduce the concentration of free unsaturated 
fatty acids321.  This reduction is likely to disrupt the activity of other enzymes that 
depend on free unsaturated fatty acids and potentially disrupt membrane trafficking.  PI 
synthesis by MBOAT7 has a strict requirement for polyunsaturated fatty acids200,281.  PI 
is phosphorylated to form phosphatidylinositol 4-phosphate (PI4P) at ERES where it is 
critically important for COPII function and ER export322.   
Knockdown of LPCAT3 
 Knockdown of LPCAT3 disrupted the localization of ERGIC-53 and markers for 
COPII and COPI vesicles.  Most dramatically, peripheral localization of β-COP was 
nearly eliminated in knockdown cells.  Knockdown also slowed retrograde trafficking of 
ERGIC-53 in response to 15°C to 37°C temperature shift and retrograde trafficking of 
GPP130 from the Golgi complex in response to BFA treatment.  Slowed retrograde 
trafficking was accompanied by increased membrane tubulation.  Taken together, these 
findings suggest that LPCAT3 knockdown promotes membrane tubulation by inhibiting 
COPI-mediated scission, thus tubules would persist longer and fusion with the ER 
would be inhibited. 
 LPCAT3 is an ER localized protein, but LPCAT3 knockdown most severely 
disrupts ERGIC and Golgi retrograde trafficking.  This suggests that the substrates 
and/or products of LPCAT3’s enzymatic activity regulate membrane trafficking, and not 
directly through interactions of LPCAT3 with trafficking machinery.  Knockdown is 
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thought to increase LPC, increase polyunsaturated acyl-CoA, and decrease 
polyunsaturated PC concentrations (Figure 5-13).  Membrane tubulation and COPI 
vesiculation is influenced by each of these changes. 
 Following LPCAT3 knockdown, the expression levels of other LPC specific 
LPATs such as LPCAT1 and LPCAT4 did not increase in a compensatory manner.  This 
was shown by Li et al. using murine adenoviral knockdown; they found that saturated 
PC of liver tissue did not increase in response to LPCAT3 knockdown140.  Ishibashi et 
al. came to a similar conclusion using siRNA treated macrophages321.  Consequentially, 
LPC concentrations rise in response to LPCAT3 knockdown; Li et al. observed a 39% 
increase140.  The positive spontaneous curvature of LPC aids in the formation of 
membrane tubules and prevents fusion264,323.  The ‘stalk’ and ‘hemifusion’ intermediates 
of early membrane fusion have high negative curvature and are energetically 
unfavorable for LPC containing membranes324.  Thus, increased LPC concentrations 
would increase the capacity of the ERGIC and Golgi to form membrane tubules and 
prevent their fusion with the ER. 
 LPCAT3 knockdown increases the concentration of free AA (and other 
polyunsaturated fatty acids) in the cell, which can then be used by other AA specific 
acyltransferases321.  There is evidence that the activity of at least MBOAT7 and DGAT1 
increases in response to elevated AA concentrations.  In the C. elegans model system, 
knockdown of the LPCAT3 orthologue increases polyunsaturated fatty acid 
incorporation into PI, an activity thought to be dependent on MBOAT7317.  The evidence 
for increased DGAT1 activity comes from LPCAT3 siRNA treated macrophages and 
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Figure 5-13.  LPCAT3 related phospholipid remodeling and membrane trafficking 
LPCAT3 and MBOAT7 acylate lysophospholipids with polyunsaturated acyl-CoA.  
Knockdown of LCPAT3 decreases the concentration of polyunsaturated PC and 
increases the concentration of LPC, polyunsaturated acyl-CoA, and PI.  LPC, 
polyunsaturated PC, and PI/PIPs have important effects on membrane curvature and 
membrane trafficking. 
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murine hepatic knockdown model systems, both of which showed elevated triglyceride 
synthesis140,321.  Altered triglyceride synthesis is not expected to affect retrograde 
membrane trafficking from the ERGIC and Golgi, but increased PI synthesis could have 
profound effects. 
 PI derived PIPs have an integral role in retrograde membrane trafficking due to 
their direct interaction and regulation of Arf1 and PLD325,326.  Increased PIP 
concentrations may overcome the activity of PIP phosphatases that maintain their 
precise localization and steep concentration gradients.  This would cause Arf1 and PLD 
to more diffusely localize to the Golgi.   This was what was observed for the Arf1 
dependent localization of β-COP in LPCAT3 knockdown cells.  β-COP lost peripheral 
cytoplasmic localization and Golgi localization became stronger and less punctate.  
Mislocalization of Arf1, COPI coatomer, and PLD would be expected to decrease the 
efficiency of COPI vesiculation leading to enhanced membrane tubulation. 
 Arf1 cycling is critical for the loading of cargo proteins into retrograde transport 
carriers64.  Mislocalization or decreased efficiency of COPI components would result in 
the depletion of SNAREs that are required for fusion of retrograde carriers with the 
ER327,328.  In this way, retrograde membrane tubules would be prevented from fusing 
with the ER in LPCAT3 knockdown cells. 
 As was discussed above in the context of LPCAT3 overexpression, the 
polyunsaturated PC produced by LPCAT3 activity contributes to negative membrane 
curvature, increased fluidity, Ld phase separation, and is preferred by some 
phospholipid remodeling and membrane binding proteins269.  Of these mechanisms, Ld 
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phase separation is of particular importance to COPI mediated retrograde transport 
from the Golgi.  COPI vesicles are depleted of highly ordered lipid raft species such as 
cholesterol and sphingolipids, an effect that is partially mediated by Arf1 binding, 
exclusively, to Ld domains
329,330.  Phase separation is also critically important for the 
fission of in vitro generated membrane tubules331.  Decreased concentrations of 
unsaturated PC at the Golgi complex would therefore inhibit COPI efficiency and 
promote long-lived membrane tubules. 
 As AGPAT3 is the only other mammalian LPAT that has been extensively 
studied in the context of membrane trafficking, it is useful to compare its activities to that 
of LPCAT3245.  Both enzymes acylate lysophospholipids using unsaturated acyl chain 
donors and their knockdown promotes Golgi membrane tubulation.  However, 
knockdown has strikingly different effects on the kinetics of tubule mediated retrograde 
trafficking.  AGPAT3 knockdown accelerates BFA stimulated Golgi recycling, ERGIC-53 
recycling, and CI-976 stimulated Golgi recycling73,245.  LPCAT3 knockdown slows 
retrograde trafficking.  AGPAT3 knockdown is thought to promote tubulation by 
decreasing the concentration of PA and consequentially, the efficiency of COPI 
budding.  I discussed how LPCAT3 knockdown could promote tubulation by decreasing 
COPI budding efficiency; however, LPCAT3 knockdown also inhibits the fusion of 
membrane tubules with the ER.  I propose that, it is this defect in membrane fusion that 
accounts for slowed retrograde trafficking in LPCAT3 knockdown cells. 
 In summary, I have shown that LPCAT3 knockdown inhibits COPI vesiculation 
and promotes the formation of membrane tubules with increased stability.  Decreased 
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vesiculation and increased tubule stability contributed to slowed retrograde trafficking 
from the Golgi and ERGIC.  I have argued that the ER localization of LPCAT3 
necessitates a mechanistic model based on changes in membrane lipid composition.  
As reduction of LPCAT3 activity has been previously shown to change the 
concentration of LPC, PI, and polyunsaturated PC, I propose that these were the 
primary mediators of knockdown effects.  In support of this argument, I have discussed 
previous reports in which changes in the concentration of these lipids has disrupted: 
Golgi membrane dynamics; the localization and activity of Arf1, COPI coatomer, and 
PLD; and Ld phase separation in retrograde transport carriers. 
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CHAPTER SIX:  Conclusions 
 The underlying focus of my research was to better understand the relationship 
between lipid modeling and membrane trafficking.  These studies began as a series of 
experiments looking at the interplay between phospholipase activity and acyltransferase 
activity.  My experiments then shifted to the role of acyltransferase activity in regulating 
protein secretion and the relative importance of individual LPAT enzymes in regulating 
secretion.  LPCAT3 was then selected for in depth study of its role in regulating 
membrane trafficking. 
 The experiments described in Chapter 2, were designed to ascertain if 
synergistic or antagonist relationship between LPAT and phospholipase activity regulate 
membrane trafficking and Golgi morphology.  Using cells co-overexpressing AGPAT3 
and one of three phospholipases, Golgi morphology, Golgi reformation, and Golgi 
recycling was investigated.  The results suggested an antagonistic relationship between 
AGPAT3 and cPLA2α activity during Golgi reformation and CI-976 induced Golgi 
recycling.  A weak synergistic relationship between AGPAT3 and iPLA1γ during the 
process of Golgi reformation was also detected. 
 To determine the LPAT enzyme isoforms that have important roles in membrane 
trafficking, a screening experiment measuring ssHRP secretion was performed.  
Chapter 3 presented the results of this screen in the testing of LPAT overexpressing 
cells for alterations in secretory trafficking.  Ten LPAT enzymes were screened and a 
broad range of phenotypes were observed.  MBOAT7 was the most effective inhibitor of 
HRP secretion, reducing extracellular HRP to 7% of control.  AGPAT5 was the most 
effect stimulator of HRP secretion, increasing extracellular HRP to 276% of control.  
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LPCAT3 was selected for further study due to its strong secretion defect (reducing 
extracellular HRP to 22% of control), putative K(x)KXX motif, and unique role in 
maintaining the asymmetry of saturated and unsaturated acyl chains between the sn-1 
and sn-2 positions of phospholipids261. 
 In the process of characterizing LPCAT3’s effect on membrane trafficking, I 
became aware of a controversy in the field of MBOAT protein topology.  Also, no 
attempts had yet been made to develop a whole protein topological map for any 
MBOAT family LPAT enzyme.  In order to resolve these questions, the transmembrane 
topological orientation of LPCAT3 was mapped by epitope tag insertion and selective 
membrane permeabilization.  This mapping was combined with a computational 
topology prediction algorithm to produce a high confidence model of LPCAT3 
transmembrane topology containing 11 transmembrane domains and a luminal active 
site.  The LPCAT3 topology model and supporting experiments were discussed in 
Chapter 4. 
 In Chapter 5, the characterization of human LPCAT3 as it affected membrane 
trafficking was reported.  LPCAT3 activity was important for regulating efficient 
retrograde trafficking to the ER, membrane tubulation, and COPI function.  These 
activities were unlike those of any other characterized LPAT enzyme and have 
important implications for the regulation of COPI trafficking and lipoprotein secretion.  
Several mechanisms were proposed by which LPCAT3 could affect retrograde 
trafficking through changes in lipid shape, protein recruitment, and lipid remodeling 
pathways. 
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Future experiments 
 I have proposed mechanisms for LPCAT3 knockdown mediated inhibition of 
COPI, promotion of membrane tubulation, and inhibition of fusion between retrograde 
membrane tubules and the ER.  Verification of these mechanisms will require additional 
studies.  An excellent place to start would be with in vitro assays and immuno-EM to 
more clearly describe how COPI vesiculation and membrane tubulation are effected by 
LPCAT3 knockdown.  Increased PIP concentrations at the Golgi could be confirmed 
through the use of PIP binding domains.  PIP binding domains can detect aberrantly 
high concentrations of PIPs at the Golgi.  It may also be possible to restore normal PIP 
concentration in LPCAT3 knockdown cells by the overexpression of DGAT1, which 
would convert excess polyunsaturated fatty acids into inert triglycerides and prevent 
their utilization by MBOAT7.  The mechanism of Ld phase separation is very difficult to 
study in cells, but its consequences may be measurable by analyzing the lipid and 
protein composition of retrograde transport carriers.  If retrograde carriers in knockdown 
cells contain higher than normal concentrations of GPI-anchored proteins, cholesterol, 
or sphingolipids, this would indicate decreased Ld phase separation. 
 These exciting findings that LPCAT3, an ER localized protein, regulates Golgi 
membrane trafficking should be encouraging to investigators of lipid remodeling and 
LPAT enzymes.  Of the many mammalian LPAT enzymes, LPCAT3 is only the second 
to be studied in the context of membrane trafficking.  Other LPAT enzymes will 
unquestionably prove of equal importance to the regulation of membrane trafficking and 
membrane tubulation.  I have also, reported the first experimentally supported full length 
transmembrane topology of a MBOAT family LPAT enzyme and characterized the C-
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terminal motifs necessary for ER-retrieval of LPCAT3.  While further research is needed 
to confirm, refute, or expand these models, the findings of this dissertation provide new 
insights into one of biology’s most complex systems. 
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